КОНТЕЙНЕР С КОНЦЕНТРИРОВАННЫМ ВЕЩЕСТВОМ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Группа изобретений относится к разведению концентрированного вещества до необходимой концентрации для перорального употребления пользователем. Представлено устройство для предоставления концентрированного контрастного вещества для орального потребления пользователем, содержащее: корпус контейнера, образующий отверстие, сообщающееся по текучей среде с внутренней частью корпуса контейнера, и включающий в себя такую разовую дозу концентрированного контрастного вещества, находящуюся во внутренней части корпуса контейнера, что внутренняя часть имеет свободное пространство для приема через отверстие объема жидкости для разведения концентрированного контрастного вещества до выбранной степени разведения, при этом разовая доза концентрированного контрастного вещества приготовлена с возможностью ее разведения до выбранной степени разведения объемом жидкости, принимаемым через отверстие, во внутренней части корпуса контейнера; крышку, соединенную с корпусом контейнера и закрывающую отверстие; и защитный ...

СТЕКЛЯННЫЕ ИЗДЕЛИЯ И СПОСОБЫ ПОВЫШЕНИЯ НАДЕЖНОСТИ СТЕКЛЯННЫХ ИЗДЕЛИЙ

Изобретение относится к стеклянному изделию. Стеклянное изделие может включать стеклянный корпус, имеющий первую поверхность и вторую поверхность. Первая поверхность стеклянного корпуса включает группу дефектов, проходящих от первой поверхности в толщину стеклянного корпуса с максимальной начальной глубиной дефекта A. Первая поверхность стеклянного корпуса может подвергаться травлению до глубины, составляющей менее чем или равной приблизительно 25% максимальной начальной глубины дефекта Aиз группы дефектов, присутствующих на первой поверхности. Когда стеклянное изделие находится под одноосной сжимающей нагрузкой, по меньшей мере часть первой поверхности находится в состоянии напряжения, и предел прочности при одноосном сжатии стеклянного изделия составляет более чем или равняется 90% предела прочности при одноосном сжатии бездефектного стеклянного изделия. Технический результат – повышение надежности стеклянного изделия. 2 н. и 13 з.п. ф-лы, 13 ил., 2 табл.

ОДНОДОЗОВЫЙ ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ ТИРЕОИДНЫХ ГОРМОНОВ Т3 И/ИЛИ Т4

Группа изобретений относится к медицине и касается однодозового фармацевтического препарата тиреоидных гормонов T3 и/или T4, подходящего для перорального введения в готовой для применения упаковке. Указанная упаковка состоит из емкости, предварительно заполненной водно-спиртовым раствором тиреоидного гормона T3 и/или тиреоидного гормона T4. Емкость представляет собой однокомпонентную пластмассовую емкость из полиэтилена низкого давления (ПЭНП) номинальным объемом 1 мл, поддающуюся сжатию рукой и имеющую модуль Юнга от 10 до 200 МПа, помещенную в запечатанный пакет-саше, состоящий из многослойной пленки, изготовленной из материалов в следующей комбинации: полиэтилен толщиной 50 мкм (5-6%), алюминий толщиной 9 мкм (5-6%) и полиэфир толщиной 12 мкм (5-6%); причем указанный пакет-саше проявляет проницаемость в отношении кислорода и водяного пара, находящуюся в диапазоне от 0,1 до 0,2 см/м/сут. Также предложено применение препарата в готовой для применения упаковки для лечения заболеваний, связанных ...

МИКРОТИСНЕНИЕ

Способ тиснения оптических дифрагирующих микроструктур в тонкой фольге типа используемой в упаковках по меньшей мере одного из объектов группы, включающей пищевые продукты, шоколад, жевательную резинку, сувениры, ювелирные изделия, одежду, табачные изделия и фармацевтическую продукцию, посредством комплекта тиснильных валиков, содержащего один или более цилиндрических тиснильных валиков и бомбированный контрвалик. Способ включает следующие операции: помещают один или более цилиндрических тиснильных валиков и бомбированный контрвалик в единственную стойку для валиков с относительно небольшими наружными размерами, способную выдерживать давление, прикладываемое к одному или более цилиндрическим тиснильным валикам и к бомбированному контрвалику; используют единственный или первый из цилиндрических тиснильных валиков, имеющий на своей поверхности (2) один или более выпуклых тиснильных элементов (1), адаптированных для тиснения микроструктуры, причем единственный или один из указанных выпуклых ...

ЩЕЛОЧНОЗЕМЕЛЬНЫЕ АЛЮМОСИЛИКАТНЫЕ СТЕКЛЯННЫЕ КОМПОЗИЦИИ С УЛУЧШЕННОЙ ХИМИЧЕСКОЙ И МЕХАНИЧЕСКОЙ СТОЙКОСТЬЮ

Описаны щелочноземельные алюмосиликатные стеклянные композиции с улучшенной химической и механической стойкостью, предназначенные для изготовления упаковок для фармацевтических продуктов. Стеклянная композиция включает в себя от 67 мол.% до 75 мол.% SiO, от 6 мол.% до 10 мол.% AlO, от 5 мол.% до 12 мол.% оксида щелочного металла и от 9 мол.% до 15 мол.% оксида щелочноземельного металла. Оксид щелочного металла содержит по меньшей мере NaO и KO, причём содержание KO меньше или равно 0,5 мол.%. Оксид щелочноземельного металла содержит CaO, MgO и необязательно BaO и SrO. Стеклянная композиция свободна от бора и соединений бора и способна к ионному обмену, тем самым способствуя химическому упрочнению стекла для улучшения механической стойкости. Коэффициент термического расширения стекла составляет менее 60·10К. 2 н. и 13 з.п. ф-лы, 21 пр., 4 табл., 1 ил.

СПОСОБ ЗАПОЛНЕНИЯ КОНТЕЙНЕРА ВСПЕНИВАЕМОЙ КОМПОЗИЦИЕЙ

Изобретение относится к способу получения композиции, содержащей микропузырьки газа. Более конкретно, изобретение относится к способу заполнения контейнера такой композицией. Способ получения контейнера, заполненного композицией ультразвукового контрастного вещества, содержащей микропузырьки газа в жидком носителе, включает продувку контейнера от воздуха газом для заполнения свободного пространства и затем заполнение контейнера указанной композицией. Затем контейнер укупоривают. Технический результат: обеспечение заполнения свободного пространства контейнера газом, идентичным используемому в микропузырьках, в требуемом количестве и вытеснение из свободного пространства контейнера воздуха, что улучшает стабильность микропузырьков при хранении. 2 н. и 8 з.п. ф-лы, 2 пр.

КОНТЕЙНЕР С ПОЛОЙ ИГЛОЙ

Изобретение относится к медицинским контейнерам для размещения и выдачи лекарства, в частности парентерального. Контейнер содержит полую иглу в зоне отверстия, а также запечатанную, за исключением отверстия для выдачи лекарства, цельную оболочку. Контейнер выполнен с возможностью выдачи лекарства при изменении, по меньшей мере, одной зоны оболочки и имеет возможность достижения или, по меньшей мере, инициирования выдачи лекарства за счет нажатия на твердую и упругую половину оболочки, которая входит в другую половину оболочки, принимая противоположную направленную внутрь контейнера кривизну, и самопроизвольно продолжает выдачу определенного объема лекарства. Раскрыто применение контейнера с инфузионной или инъекционной иглой для инфузии или инъекции лекарства. Технический результат заключается в упрощении конструкции и облегчении введения лекарства. 2 н. и 11 з.п. ф-лы, 6 ил.

МНОГОСЛОЙНЫЙ ПЛАСТИКОВЫЙ ПОЛИМЕРНЫЙ КОНТЕЙНЕР ДЛЯ ХРАНЕНИЯ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ

Изобретение имеет отношение к многослойному пластиковому полимерному контейнеру для хранения композиции. Контейнер включает внутренний слой и внешний слой в непосредственном контакте с композицией и окружающей средой соответственно, центральный слой барьера газа и два промежуточных адгезивных слоя между центральным слоем и внешним и внутренним полимерными слоями. Внешний и внутренний слои включают смесь полимеров и, по меньшей мере, один разветвленный полиолефин. Технический результат - получение многослойных пластиковых полимерных контейнеров для хранения жидких или нежидких стерильных фармацевтических композиций, включающих водные или неводные растворители. 19 з.п. ф-лы, 14 табл., 8 ил., 10 пр.

КАПСУЛА ДЛЯ ПРИМАНКИ ДЛЯ ОРАЛЬНОЙ ИММУНИЗАЦИИ ДИКИХ ПЛОТОЯДНЫХ ЖИВОТНЫХ ПРОТИВ БЕШЕНСТВА

Полезная модель относится к ветеринарии и предназначена для сохранения целостности приманки для оральной иммунизации диких плотоядных животных против бешенства при её сбрасывании с летательных аппаратов. Твердая капсула цилиндрической формы с полусферическими концами объемом 30-100 мл имеет растворимую в организме животного стенку, отверстия диаметром 5-10 мм и линию перфорации вдоль длинной оси капсулы. В капсулу помещается приманка для оральной иммунизации диких плотоядных животных, содержащая контейнер с вакциной против бешенства. При ударении капсулы с приманкой о поверхность земли после ее сбрасывания с летательного аппарата происходит упругая деформация капсулы и разрушение оболочки капсулы по линии перфорации и между отверстиями. При этом сама приманка и контейнер с вакциной внутри приманки остаются целыми. В случае, когда капсула при ударе о поверхность земли не разрушается, отверстия в капсуле обеспечивают свободное распространение специфического запаха от приманки для привлечения ...

Контейнер для медицинских изделий

Полезная модель относится к медицинскому оборудованию и может быть использована для повышения надежности и удобства использования при хранении и транспортировке различных медицинских изделий и препаратов, в том числе и биологических проб. Контейнер для медицинских изделий содержит коробчатый корпус и крышку, при этом на краю стенки корпуса закреплен съемный держатель для бейджика-носителя визуальной информации в виде бирки, выполненный в форме изогнутой пластины, верхний конец которой кругообразно загнут в сторону стенки корпуса контейнера с образованием внутреннего плоского крючка-зажима, обеспечивающего закрепление держателя на стенке корпуса, а на противоположной наружной стороне пластины в верхней части размещен фигурный Т-образный выступ в виде наружного крючка для навешивания бейджика-носителя визуальной информации.

ДЕРЖАТЕЛЬ ДЛЯ СТАКАНА

Полезная модель относится к принадлежностям для удерживания стаканов с легковесным содержимым, преимущественно для стаканов с попкорном. Держатель для стакана содержит, по крайней мере, одну пластину из пластика или из металла, на которой выполнен заодно с пластиной верхний отгиб, а также может быть выполнен нижний отгиб. Предпочтительно верхний отгиб в виде язычка с захватом шарнирно соединен с пластиной и с нижним отгибом. Возможно выполнение держателя, в котором верхний и нижний отгибы жестко соединены с пластиной. Еще в одной конструкции держателя есть дополнительная пластина, с которой соединен нижний отгиб, при этом в основной пластине под верхним отгибом сделан проем, в который входит нижний отгиб дополнительной пластины. Сами пластины между собой могут быть склеены, спаяны или скреплены при помощи механического крепежа. 2 з.п. ф-лы, 6 ил.

КОНТЕЙНЕР С ТРАНСПОРТНОЙ СРЕДОЙ - КОНСЕРВАНТОМ ТУРДЫЕВА ДЛЯ ВЗЯТИЯ, ХРАНЕНИЯ (В ТОМ ЧИСЛЕ АРХИВНОГО) И ТРАНСПОРТИРОВАНИЯ ПРЕПАРАТОВ КАЛА

Техническое решение относится к лабораторной посуде, а именно к пробиркам, и может быть использовано в химических, физических, биологических и клинико-диагностических лабораториях для сбора, хранения и транспортирования биоматериала, а также в домашних условиях для самостоятельного забора биоматериала.Технический результат вышеприведенной задачи достигается за счет создания контейнера с транспортной средой - консервантом Турдыева для взятия, хранения (в том числе архивного) и транспортирования препаратов кала, представляющего собой контейнер и состоящего из баночки, крышки, шпателя, содержащий некоторое количество транспортной среды (консерванта) и отличающийся тем, что шпатель выполнен отдельным с шириной поперечного сечения, по меньшей мере, в два раза меньшей внутреннего диаметра горловины баночки, что обеспечивает свободное прохождение шпателя совместно с биоматериалом, при этом количество транспортной среды, а именно консерванта Турдыева, находится в диапазоне от 1 мл до 2/3 объема ...

ОДНОРАЗОВЫЙ КОНТЕЙНЕР ДЛЯ ХРАНЕНИЯ БИОЛОГИЧЕСКОГО МАТЕРИАЛА, ИСПОЛЬЗУЕМОГО В МИКРОХИРУРГИИ ГЛАЗА, С УСТРОЙСТВОМ ДЛЯ ОБЕСПЕЧЕНИЯ ОДНОРАЗОВОСТИ ИСПОЛЬЗОВАНИЯ

Изобретение относится к медицинской технике, а именно к офтальмологии. Одноразовый контейнер для хранения биологического материала, используемого в микрохирургии глаза, содержит корпус, на внутренней поверхности которого в гнезде запорного механизма содержится пружина из эластопласта, соединенная с фиксирующим элементом и закрытая крышкой пружины. При этом корпус разъемно соединен с крышкой при наличии расположенного между ними и наложенного на торец корпуса уплотнительного кольца, выполненного с возможностью разрушения фиксирующего элемента при открытии крышки. На внутренней поверхности торцевой части выполнены гнездо крышки, совмещенное с гнездом запорного механизма, и расположенный напротив гнезда крышки зуб для надрыва уплотнительного кольца при открытии крышки. Фиксирующий элемент выполнен с возможностью перемещения в гнездо крышки под действием пружины. Достигается простота конструкции, удобство эксплуатации и надежность хранения биологического материала. 6 з.п. ф-лы, 1 пр., 7 ил.

Первичное упаковочное средство и способ производства первичного упаковочного средства

Группа изобретений относится к области фармацевтики и может быть использована для упаковки лекарственных средств. Первичное упаковочное средство (1) для лекарственных средств включает основной корпус (3), содержащий полимерный материал и имеющий по меньшей мере одну стенку (5) с наружной поверхностью (7) и с по меньшей мере одной внутренней поверхностью (9). При этом наружная поверхность (7) снабжена газонепроницаемым покрытием (11), а внутренняя поверхность (9) снабжена газонепроницаемым внутренним покрытием, на котором расположен, по меньшей мере, местами внутренний функциональный слой, который исключен по меньшей мере в одной свободной области. Группа изобретений относится также к способу производства указанного первичного упаковочного средства. Группа изобретений позволяет расширить область применения при сохранении безопасности первичной упаковки. 2 н. и 11 з.п. ф-лы, 1 ил.

МЕШОК ДЛЯ УПАКОВКИ БИОЛОГИЧЕСКОГО МАТЕРИАЛА, ПОЛОСА, СОСТАВЛЕННАЯ ИЗ ТАКИХ МЕШКОВ, И КОМПЛЕКТ, ВКЛЮЧАЮЩИЙ ТАКОЙ МЕШОК И ПОДВЕШИВАЮЩЕЕ УСТРОЙСТВО ДЛЯ НЕГО

... 1. Пакет для упаковки биологического материала, такого как сперма животных, образованный двумя пластмассовыми стенками, соединенными с формированием кармана для приема указанного материала, и включающий наполнительный канал, сообщающийся с указанным карманом для обеспечения его наполнения, причем пакет снабжен, по меньшей мере, одной парой отверстий, расположенных с обеих сторон от наполнительного канала и предназначенных для подвешивания пакета на проходящих через эти отверстия пальцах, представляющих собой часть несущей конструкции, отличающийся тем, что, по меньшей мере, одно из отверстий имеет продолговатую форму, проходит поперечно наполнительному каналу и включает участок, формирующий точку жесткости. ! 2. Пакет по п.1, отличающийся тем, что участок, формирующий точку жесткости, является областью, в которой указанное одно из отверстий имеет уменьшенную ширину. ! 3. Пакет по п.2, отличающийся тем, что указанное одно из отверстий имеет на виде спереди форму двух частично наложенных ...

СТОЙКИЕ К РАССЛАИВАНИЮ СТЕКЛЯННЫЕ КОНТЕЙНЕРЫ

... 1. Стойкий к расслаиванию стеклянный контейнер, включающий:стеклянное изделие, имеющее стеклянный корпус, простирающийся между внутренней поверхностью и внешней поверхностью и определяющий внутренний объем;внутреннюю область, простирающуюся с глубины примерно 10 нм под внутренней поверхностью корпуса в толщу корпуса и имеющую постоянную слоевую однородность, так что корпус является стойким к расслаиванию.2. Стеклянный контейнер по п. 1, где стеклянное изделие выполнено из композиции стекла, которая имеет температуру, отвечающую 1000 пуаз, составляющую менее, либо равную примерно 1700°C.3. Стеклянный контейнер по п. 1, где внутренняя область имеет толщину Tпо меньшей мере примерно 100 нм.4. Стеклянный контейнер по п. 1, где стеклянное изделие выполнено из композиции стекла, которая содержит менее, либо примерно 1,0 мол.% оксидов бора и менее, либо примерно 1,0 мол.% соединений, содержащих бор.5. Стеклянный контейнер по п. 1, где стеклянное изделие выполнено из композиции стекла, которая ...

ЛАКТАМСОДЕРЖАЩИЕ СОЕДИНЕНИЯ И ИХ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха

... 1. Соединение, выбранное из группы, включающей 1-(3-хлорфенил)-7-оксо-6-[4-(2-оксо-1(2Н)пиридинил)фенил]-4,5,6,7-тетрагидро-1Н-пиразоло[3,4-с]пиридин-3-карбоксамид; 3-(1-гидрокси-1-метилэтил)-1-(4-метоксифенил)-6-[4-(2-оксо-2Н-пиридин-1-ил)-фенил]-1,4,5,6-тетрагидропиразоло[3,4-с]пиридин-7-он; или их фармацевтически приемлемые соли. ! 2. Соединение по п.1, представляющее собой соединение формулы ! ! или его фармацевтически приемлемая соль. ! 3. Соединение по п.2, представляющее собой соединение формулы ! ! 4. Соединение по п.1, представляющее собой соединение формулы ! ! или его фармацевтически приемлемая соль. ! 5. Соединение по п.4, представляющее собой соединение формулы ! ! 6. Соединение по любому из пп.1-5, предназначенное для лечения тромбоэмболического заболевания. ! 7. Соединение по п.6, отличающееся тем, что тромбоэмболическое заболевание выбрано из группы, состоящей из артериальных сердечно-сосудистых тромбоэмболических заболеваний, венозных сердечно-сосудистых тромбоэмболических ...

УСТРОЙСТВО ДЛЯ ПОЖИЗНЕННОГО ПРИЁМА ПЕРЕМЕННЫХ ДОЗ ГЕРОПРОТЕКТОРА, ПОВЫШЕНИЯ ПОСТАДАПТАЦИИ ГОРМЕЗИС

ИММУНОГЕННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ КОНЪЮГИРОВАННЫЕ КАПСУЛЬНЫЕ САХАРИДНЫЕ АНТИГЕНЫ, И ИХ ПРИМЕНЕНИЕ

ИНГАЛЯЦИОННАЯ ЛЕКАРСТВЕННАЯ ФОРМА РАПАМИЦИНА ДЛЯ ЛЕЧЕНИЯ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ

ДВУХКАМЕРНЫЙ КОНТЕЙНЕР И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

... 1. Способ изготовления двухкамерного контейнера (100), включающего в себя камеру (61) для хранения лекарственного вещества и камеру (62) для хранения медицинского раствора, отделенные друг от друга участком (30) непрочного сварного шва, где способ включает в себя этапы:подготовки первого листообразного элемента (10), включающего в себя первую часть (11), формирующую камеру для хранения лекарственного вещества, и первую часть (12), формирующую камеру для хранения медицинского раствора, стороны которых (11A, 12A) соединяют друг с другом, а также второго листообразного элемента (20), включающего в себя вторую часть (21), формирующую камеру для хранения лекарственного вещества, и вторую часть (22), формирующую камеру для хранения медицинского раствора, стороны (21A, 22A) которых соединяют друг с другом; иформирования указанной камеры (61) для хранения лекарственного вещества и указанной камеры (62) для хранения медицинского раствора посредством соединения указанного первого листообразного элемента ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ИМЕЮЩЕЕ СЛАБУЮ РАСТВОРИМОСТЬ В ВОДЕ

... 1. Фармацевтическая композиция, содержащая малорастворимое в воде лекарственное средство и по меньшей мере одно производное целлюлозы.2. Фармацевтическая композиция по п. 1, дополнительно содержащая по меньшей мере один полисахарид природного происхождения.3. Фармацевтическая композиция по п. 1, в которой малорастворимое в воде лекарственное средство представляет собой ионообменную смолу.4. Фармацевтическая композиция по п. 3, где ионообменная смола представляет собой полистиролсульфонат.5. Фармацевтическая композиция по п. 1, в которой производное целлюлозы представляет собой по меньшей мере одно производное целлюлозы, выбранное из группы, состоящей из гидроксипропилметилцеллюлозы, гидроксипропилцеллюлозы и метилцеллюлозы.6. Фармацевтическая композиция по любому одному пп. 1-5, препарат из которой представляет собой суспензию.7. Фармацевтическая композиция по п. 6, где препарат представляет собой желеобразную суспензию.8. Фармацевтический препарат, в котором фармацевтическая композиция ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ СЕРДЦА

... 1. Фармацевтическая композиция, содержащая клетки, коммитированные на формирование ткани сердца, и по меньшей мере один фармацевтически приемлемый наполнитель, в которой указанный по меньшей мере один фармацевтически приемлемый наполнитель представляет собой раствор консерванта.2. Фармацевтическая композиция по п.1, в которой клетки, коммитированные на формирование ткани сердца, получают в соответствии с принятыми международными стандартами изготовления лекарственных препаратов.3. Фармацевтическая композиция по п.1, в которой указанный раствор консерванта выбран из группы, включающей раствор консервантов, которые позволяют осуществлять криоконсервацию при температурах от -196°С до 0°С, и растворы консервантов, которые позволяют осуществлять криоконсервацию при температурах от 0°С до 40°С.4. Фармацевтическая композиция по п.1, в которой указанный раствор консерванта представляет собой раствор консерванта, который может содержать ионы, рН-буферные растворы, непроникающие агенты, коллоидные ...

КОМБИНАЦИИ ИНГИБИТОРА PI3K/AKT С ИНГИБИТОРОМ HER3/EGFR И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

СТЕКЛЯННЫЕ ИЗДЕЛИЯ И СПОСОБЫ ПОВЫШЕНИЯ НАДЕЖНОСТИ СТЕКЛЯННЫХ ИЗДЕЛИЙ

ДОЗИРУЮЩИЙ КОЛПАЧОК ДЛЯ БУТЫЛКИ С ПРОДУКТАМИ ЖИДКОЙ ИЛИ ВЯЗКОЙ КОНСИСТЕНЦИИ И БУТЫЛКА, СОДЕРЖАЩАЯ ТАКОЙ КОЛПАЧОК ДЛЯ БУТЫЛКИ

... 1. Дозирующий колпачок для бутылок с продуктами жидкой или вязкой консистенции, включающий в себя корпус колпачка, выполненный с возможностью установки на бутылке и включающий в себя питающую полость и верхний элемент, выполненный с возможностью перемещения относительно этого корпуса между неактивной конфигурацией, в которой дозирующее отверстие для продукта закрыто, и активной конфигурацией, в которой это дозирующее отверстие открыто на наружную сторону и сообщается с питающей полостью, отличающийся тем, что этот колпачок (10, 110) имеет боковую стенку, образованную корпусом (20, 120), и, причем в упомянутой неактивной конфигурации верхняя стенка состоит полностью из верхней стенки верхней части (30, 130), причем этот корпус и эта верхняя часть имеют дополнительные частично сферические поверхности (21B, 41, 121B, 141), соответственно вогнутые и выпуклые, выполненные с возможностью скольжения относительно друг друга, и соединены при помощи дополнительных удерживающих и направляющих элементов ...

Method of stroing a vaccine containing an aluminium adjuvant

Flexible matter bottle at carrying bottom.

Method of stroing a vaccine containing an aluminium adjuvant

MEDICAL CONTAINER

SOCKET TO THE ADMISSION OF A TROPFERHALSES AND APPROPRIATE PACKING AND KIT

TABLET PACKAGING EQUIPMENT

IMPROVEMENT OF A TROCKENPULVERINHALATORS

DISCHARGE DEVICE

CONTAINER FOR TO GIVING LIQUID MEDICINES

COMPACTIBLE BAGS FROM POLYETHYLENE

A BLISTERFILM FROM MULTI-LAYER LAMINATE

USE OF A CONTAINER FROM PLASTICS WITH INORGANIC ADDITIVE

SUCTION BOTTLE FROM PLASTIC

MEDICAL PRODUCT WITH TIOTROPIUM IN A DAMPPROOF CONTAINER

CONTAINER FÜR EINE MEHRZAHL VON EINZELDOSEN SOWIE APPLIKATOR FÜR DERARTIGE CONTAINER

The invention relates to a container (3) for a plurality of individual doses of a liquid substance in which the individual doses are separately packed in a gas-tight manner and can be released separately. Said invention is characterised in that the container (3) comprises an essentially flat support film having a plurality of gas-tight cavities (33) and discharge channels (32) that are arranged on the periphery of the support film and that discharge at a distance from the periphery of the support film, such that end incisions are provided on the periphery starting in a transversal manner in relation to the discharge channels (32) and arranged at a distance therefrom. The discharge channels (32) are released when folding and pulling on the tabs formed by the incisions (30) and by ripping and separating in a manner that is transversal to the axis of the discharge channels (32).

PROCEDURE AND DEVICE FOR PROPORTIONING A LIQUID PRODUCT

CHILD-SAFE SINGLE PORTION PACKING AND SEPARATION MEDICINE PACKING

TRANSFER DEVICE BY SUCKING.

MEDICINE DONOR.

ASEPTI CONTAINER POURING SPOUT.

PROCEDURE AS WELL AS PACKING FOR KEEPING AND DELIVERING STERILE LIQUID QUANTITIES.

METHOD FOR THE PRODUCTION OF FREEZINGDRIED DOSAGES IN A BLISTER PACK FROM MULTI-LAMINATE

CONTAINER FOR REACTIVE PHARMACEUTICAL PRODUCTS.

DRUG DELIVERY AND METERING UNIT WITH A DOUBLE DELIVERY OPENING.

CARTOUCHE OF A MEDICAL INSTRUMENT, IN PARTICULAR DIALYSIS EQUIPMENT

MULTIPART CONTAINER FOR STERILE CELEBRATIONS OF PRODUCTS.

ARRANGEMENT TO THE DRUG DELIVERY.

STERILISIERBARES SET ZUR SELBSTINJEKTION ZUM EINMALIGEN GEBRAUCH

A sterilisable set for self-injecting drugs comprises a typical drug-mixing and injecting syringe (not shown), a filter, disposed within a filter holder, to eliminate particulate matter and an auxiliary container. The handling end of the syringe plunger rod has a ring which may be opened. The container 51 such as a spoon preferably made of light metal with a heat resistant handle 54 contains fluid to be drawn up. The container 51 and optionally the filter are preferably sealed with a tear off film 52. The set is preferably contained in a "cigarette box" type cardboard container 62 and may be dispensed from a vending machine and is recyclable. The set is intended for use to prevent infection in the course of self administration of drugs.

DEVICE FOR THE COMPUTATION OF THE DOSAGE OF ELIXIER FOR THE BODY WEIGHT OF THE PATIENT

ENGINE PUMP UNIT

PLASTIC CONTAINER FOR LIQUID MEDICINES

EQUIPMENT FOR REMOVING FROM PRESERVATIVE FROM LOESUNGEN.

USE OF THE DEVICE TO THE APPLICATION OF DRUG SUSPENSIONS AND PROCEDURE FOR THE PRODUCTION OF A HOMOGENEOUS MIXTURE OF THIS SUSPENSION.

CONTAINER FOR PARENTERAL LIQUIDS

PHIOLE FOR IMPLANT

OWNER FOR THE FREEZING DRYING PROCESS OF MEDICINE SOLUTIONS

LIP MEDICATION APPLICATOR

Recyclable package comprising a flexible pouch

A recyclable flexible pouch (10) whose constituent parts can be easily deconstructed and placed into appropriate recycling streams. Recyclable flexible pouches (10) having a product disposed therein are also disclosed, along with kits containing same. In addition, methods of producing the recyclable flexible pouches and packaged products are also disclosed.

Smart caps for medication containers

A cap for a medication container may include: at least one pressure sensor; an air supplying unit; and a controller. The controller may be configured to: receive a first air pressure measurement form inside the medication container, form the at least one pressure sensor; control the air supply unit to supply air at a predetermined pressure for a predetermined amount of time; receive a second air pressure measurement from inside the medication container, form the at least one pressure sensor; and perform an output operation using the first and second air pressure measurements.

GLASS ARTICLES WITH LOW-FRICTION COATINGS

A coated pharmaceutical package comprising: a glass body comprising a first surface and a second surface opposite the first surface, wherein the glass body is a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container; and a low-friction coating positioned on at least a portion of the first surface of the glass body, the low-friction coating comprising: a polymer selected from the group consisting of polyimides, fluoropolymers, silsesquioxane-based polymers, and silicone resins; and a coupling agent layer disposed between the polymer and the first surface of the glass body, wherein the coefficient of friction of the portion of the coated pharmaceutical package with the low-friction coating is at least 20% less than a coefficient of friction of a surface of an uncoated pharmaceutical package formed from the same glass composition.

Packaged medicine

Provided is a packaged medicine capable of preventing electrode degradation over a long period of time, and reliably emitting a signal once ingested, even if a long time passes from production to ingestion. The packaged medicine is provided with: a solid formulation which includes medicine powder and a micro device; a container having a solid formulation-accommodating space and accommodating the solid formulation in the solid formulation-accommodating space; and an inert gas which fills the solid formulation-accommodating space. The micro device is provided with: two electrodes having different ionization tendencies; and an emission part which emits a signal using electromotive force that is generated when the electrodes are in contact with an electrolyte.

Perforated capsules

The present invention relates to gelatin capsules containing microbeads. The capsule has perforations that enhance the dissolution of the capsule.

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Abstract The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogeniccompositions.

Improved storage of parenterally administerable products

Case with pill receiving sleeves for storing and dispensing pills

Apparatus, system and method for detection and delivery of a medicinal dose

An apparatus is disclosed as part of a system for tracking and confirming delivery of a medicinal dose to a user. The apparatus includes a detector. The detector is secured to and communicatively coupled to the user and is capable of detecting a current flow through the user's body. The current flow is produced when the user makes contact with the apparatus. The apparatus includes at least two contact areas connected to a power source where a circuit and, hence, a current path is completed through the user's body as the user makes contact with the apparatus. The current flow is detected by the detector, which is coupled to the user. Also disclosed is an apparatus for tracking and confirming delivery of a medicinal dose to a user where the apparatus includes an acoustic detector. Upon loading the dose into a chamber an acoustic vibration is generated. The vibration is detected and correlated with a current flow that is produced when the user makes contact with the apparatus. The combined ...

A container and method for storing a sample

A container, comprising: a body; and, a closure; wherein the closure has a lid hinged to a ring mounted on the body, the lid moveable from an open position to a closed position; wherein the lid has a tab hinged thereto for: inserting into and engaging a slot formed in the ring as the lid is moved to the closed position from the open position to thereby lock the lid in the closed position; or, receiving and engaging a pin head of a pin mounted on the ring in a hole formed in the tab to thereby hold the lid in the closed position, the pin configured to detach from the ring when the tab and lid are returned to the opened position.

Cefuroxime safety delivery system

The present invention relates to safety delivery systems for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety delivery system according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a reconstitution syringe with a male luer fitting sterile-filled with 0.1 ml of isotonic salt solution per mg cefuroxime in the perforable vial and a vial adapter with a female luer fitting or one or more needles with female luer fitting, and (c) one or more sterilized delivery syringes with male luer fitting, each delivery syringe being capable of holding at least 0.1 ml of ejectable liquid and containing a marking indicating a fill volume of 0.1 ml of ejectable liquid.

Insertion and bias mechanism

A drawer assembly is disclosed that includes a removable container and a receiving tray. The container has a housing having at least one shaped surface and at least one horizontal alignment element coupled to and projecting from the housing. The receiving tray has a base having a redirection feature and at least one horizontal alignment hole in the base that is configured to accept the horizontal alignment element. The container and receiving tray are configured such that downward motion of the container with the shaped surface of the housing in contact with the redirection feature of the base induces a lateral motion of the container according to the engagement of the shaped surface and the redirection feature that causes the horizontal alignment element to slide into the horizontal alignment hole.

Medicament cartridges with non-standard dimensions

A method of closing the distal end of an ampoule (322) is shown. The ampoule (322) has a variable diameter head portion (331) having a locating surface (350) and an opening. A septum (327) is positioned on the opening and secured to the head portion (331) with a ferrule (324) using a plunger. The plunger exerts a force in a proximal direction to press the ferrule (324) on the head portion (331) until the press causes the ferrule (324) to contact the locating surface (350). Further, the ampoule (322) for use in a cartridge (320) for a drug delivery device (100) has non- standard dimensions to provide a coding system to reduce the risk of a user dispensing the wrong medicament from the drug delivery device (100).

Crushing bags and methods for use and manufacture

A pill crusher pouch is constructed of a flexible sheet material having an open top and an open bottom, wherein the open bottom is dimensionally smaller than the open top, forming a funnel-like internal pouch cavity, and a crease near the bottom of the pouch that allows a user to easily fold the pouch to form a temporary seal that prevents crushed pill product from dispensing through the open bottom until the user unfolds the pouch.

Gamma-irradiation sterilized polyethylene packaging

Sterile container for medical applications

GLASS COMPOSITIONS WITH IMPROVED CHEMICAL AND MECHANICAL DURABILITY

A glass composition comprising: from about 70 mol.% to about 80 mol.% SiO2; from about 4 mol.% to about 8 mol.% alkaline earth oxide, the alkaline earth oxide comprising CaO and from about 3 mol.% to about 7 mol.% MgO; X mol.% A120 3 , wherein X is from about 5 to about 7; and Y mol.% alkali oxide, wherein the alkali oxide comprises Na20 in an amount greater than 8 mol.%, and the glass composition is free of boron and compounds of boron.

Pressure-regulating vial adaptors

ICUMM.478WO2 PRESSURE-REGULATING VIAL ADAPTORS In certain embodiments, a vial adaptor comprises a housing configured to couple the adaptor with a vial, an access channel, a regulator channel, and a regulator assembly. The access channel is configured to facilitate withdrawal of fluid from the vial when the adaptor is coupled to the vial. The regulator channel is configured to facilitate a flow of a regulating fluid from the regulator assembly to compensate for changes in volume of a medical fluid in the vial. The regulator assembly can include a valve configured to transition between a closed configuration and an opened configuration. - 94 - ...

ALKALINE EARTH ALUMINO-SILICATE GLASS COMPOSITIONS WITH IMPROVED CHEMICAL AND MECHANICAL DURABILITY

Disclosed are glass compositions comprising from 67 mol.% to about 75 mol.% SiO2; from about 6 mol.% to about 10 mol.% A120 3; from about 5 mol.% to about 12 mol.% alkali oxide, 5 wherein the alkali oxide comprises Na20 and K20 and the K20 is present in an amount less than or equal to 0.5 mol.%; and from about 9 mol.% to about 15 mol.% of alkaline earth oxide, the alkaline earth oxide comprising greater than 0 mol. % and less than or equal to 3.5 mol. % MgO and from about 2 mol. % to about 5 mol% CaO, wherein a ratio of a concentration of MgO to the sum of the concentration of divalent cations (MgO:RO) is less than 0.3 and the 10 glass composition is susceptible to strengthening by ion-exchange. ...

Glass compositions with improved chemical and mechanical durability

The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol.% to about 80 mol.% SiO ...

Childproof highly-inert bag packaging for individually dosed films containing an active ingredient

The invention relates to a childproof packaging for individual doses (1), in particular for preparations for administration in film form, wherein the packaging constitutes a bag produced by sealing, which has at least on each side a covering layer which is provided at least on one side with local weak points (4) which do not touch the edge of the packaging, wherein the local weak points (4) form a cohesive pattern which runs around the individual dose (1) in an arc or a curve and overlaps an angular region of at least 90° when considered from the main area of the individual dose (1).

Pharmaceutical solution-dispensing device

Provided is a pharmaceutical solution-dispensing device capable of shortening the time for dispensing pharmaceutical solutions into a dosing bottle. The pharmaceutical solution-dispensing device, which dispenses pharmaceutical solutions accommodated in pharmaceutical solution bottles into a dosing bottle, is provided with: a pharmaceutical solution stirrer that stirs a pharmaceutical solution inside a pharmaceutical solution bottle; a bottle holder that holds a plurality of pharmaceutical solution bottles including a first bottle accommodating a pharmaceutical solution (G) and a second bottle accommodating a pharmaceutical solution (B); and a control unit that controls the actions of the pharmaceutical solution-dispensing device. The control unit operates the pharmaceutical solution stirrer to stir the pharmaceutical solution (B) while the pharmaceutical solution (G) is being dispensed from the first bottle into the dosing bottle.

Ophthalmic composition for treatment of dry eye disease

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1 % (w/v] cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Improved storage and maintenance of blood products

Fluid dispenser tip with recessed dispensing nozzle

Device for connecting a receptacle and a container and ready-for-use set comprising same

Implanter device for subcutaneous implants

Liquiflash particles and method of making same

Универсальный иглосъемник

Полезная модель относится к медицинскому оборудованию для сбора бесконтактным способом, хранения, дезинфекции и утилизации медицинских отходов различной этиологии и может быть использована в лечебно-профилактических, ветеринарных и других специализированных учреждениях. Универсальный иглосъемник (1) устанавливается в емкость (8) для сбора медицинских отходов и выполнен из упругого материала. Универсальный иглосъемник (1) имеет цанговый зажим, образованный упругими лепестками (2), которые выполнены треугольными и расположены относительно друг друга с промежутками и под углом к плоскости иглосъемника. Толщина и ширина лепестков (2) выполнены переменными. Концы лепестков (2) образуют отверстие (3), которое имеет диаметр, равный диаметру резьбы карпульного шприца. Иглосъемник (1) выполнен с дополнительным отверстием (4) для откручивания сильно затянутых резьбовых соединений игл (5) в шприце (6). Прорезь (7) служит для проведения иглы из дополнительного отверстия (4) в отверстие (3). Технический результат заключается в повышении эксплуатационных качеств универсального иглосъемника. 3 ил. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 194 008 U1 (51) МПК A61L 11/00 (2006.01) A61J 1/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК A61L 11/00 (2019.08); A61J 1/00 (2019.08) (21)(22) Заявка: 2019115508, 21.05.2019 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Маврин Владлен Николаевич (RU) Дата регистрации: 25.11.2019 (45) Опубликовано: 25.11.2019 Бюл. № 33 1 9 4 0 0 8 R U (54) Универсальный иглосъемник (57) Реферат: Полезная модель относится к медицинскому оборудованию для сбора бесконтактным способом, хранения, дезинфекции и утилизации медицинских отходов различной этиологии и может быть использована в лечебнопрофилактических, ветеринарных и других специализированных учреждениях. Универсальный иглосъемник (1) устанавливается в емкость (8) для сбора медицинских отходов и выполнен из ...

Крышка для укупоривания флаконов с инфузионными и инъекционными растворами

Полезная модель относится к медицинской технике, а именно упаковке для стерильных жидкостей, более конкретно к укупорочным средствам - колпачкам для наполненных медицинскими жидкостями емкостей, и может быть использована в медицинской промышленности для стерильной укупорки емкостей, в частности наполненных жидкостями для инъекции или переливания, с возможностью обеспечения в укупорочном средстве мест прокола для введения в емкость устройства для забора стерильной жидкости (например шприца) и последующего безопасного извлечения этого устройства с необходимым количеством жидкости. Техническим результатом является обеспечение надежности фиксации уплотнительного элемента. Крышка для укупоривания флаконов с инфузионными и инъекционными растворами содержит колпачок, в верхней части которого расположен, по меньшей мере, один стерильный порт, а также уплотняющий элемент, зафиксированный мембраной, приваренной к колпачку, при этом мембрана выполнена из того же материала, что и колпачок. 4 з.п. ф-лы, 2 ил. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 209 527 U1 (51) МПК B65D 41/28 (2006.01) B65D 51/20 (2006.01) B65D 55/08 (2006.01) A61J 1/00 (2006.01) A61J 1/14 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК B65D 41/28 (2022.01); B65D 51/20 (2022.01); B65D 55/08 (2022.01); A61J 1/00 (2022.01); A61J 1/14 (2022.01) (21)(22) Заявка: 2021133147, 16.11.2021 16.11.2021 Дата регистрации: 16.03.2022 Приоритет(ы): (22) Дата подачи заявки: 16.11.2021 (45) Опубликовано: 16.03.2022 Бюл. № 8 2 0 9 5 2 7 R U (54) Крышка для укупоривания флаконов с инфузионными и инъекционными растворами (57) Реферат: Полезная модель относится к медицинской устройства с необходимым количеством технике, а именно упаковке для стерильных жидкости. Техническим результатом является жидкостей, более конкретно к укупорочным обеспечение надежности фиксации средствам - колпачкам для наполненных уплотнительного элемента. Крышка для медицинскими жидкостями ...

Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis

A method of preparing a medical solution includes the steps of a) providing a solution having one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH of from 2.5 to 5.0, and b) terminal sterilization of the compartment and the contents therein. The solution can be used for manufacturing a medicament for peritoneal dialysis.

Adhesive patch-containing package bag and method for storing adhesive patch

The present invention relates to an adhesive patch-containing package bag 1, having: a package bag 8; and an adhesive patch 10 stored inside the package bag 8, wherein the adhesive patch 10 has a backing 12, an adhesive layer 14 laminated on at least one side of the backing 12 and containing ropinirole and/or a pharmaceutically acceptable salt thereof, and a release liner 16 covering the adhesive layer 14, and a relative humidity at 4° C. is maintained at 35% or higher inside the package bag 8.

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Drug suspension agent and method of manufacture thereof

A drug suspension agent and method of making same is used for curing or preventing diseases, or adjusting the physiological function of a human or animal body by drug information without contacting the skin. The basic configuration of the drug suspension agent consists of a drug holder (1), a container (4) and a connector (5). The contents (2) are drugs having pharmacological activity.

FUSED QUARTZ TUBING FOR PHARMACEUTICAL PACKAGING

A high silica glass composition comprising about 92 to about 99.9999 wt. % SiOand from about 0.0001 to about 8 wt. % of at least one dopant selected from AlO, CeO, TiO, LaO, YO, NdO, other rare earth oxides, and mixtures of two or more thereof. The glass composition has a working point temperature ranging from 600 to 2,000° C. These compositions exhibit stability similar to pure fused quartz, but have a moderate working temperature to enable cost effective fabrication of pharmaceutical packages. The glass is particularly useful as a packaging material for pharmaceutical applications, such as, for example pre-filled syringes, ampoules and vials. 1. A silica glass composition comprising about 92 to about 99.9999 wt. % SiOand about 0.0001 to about 8 wt. % of a dopant selected from AlO , GeO , GaO , CeO , ZrO , TiO , YO , SrO , BaO , a rare earth oxide , or mixtures of two or more thereof , wherein a fused glass article formed from the composition has a total extractable metal concentration of about 8 mg/L or less when subjected to HCl digestion , the total extractable metal concentration being represented by the total concentration of Al , B , Na , Ca , K , Li , Ba , and Mg extracted upon HCl digestion.2. The glass composition of claim 1 , wherein the BOconcentration is about 2.5 wt % or less.3. The glass composition of comprising about 96 to about 99.9999 wt % SiO.4. The glass composition of claim 1 , wherein the total extractable metal concentration is about 5 mg/L or less.5. The glass composition of claim 1 , wherein the total extractable metal concentration is about 1 mg/L or less.6. The glass composition of claim 1 , wherein the glass composition exhibits a working point temperature in the range of from about 1 claim 1 ,000 to about 2 claim 1 ,000° C.7. The glass composition of claim 1 , wherein the glass composition exhibits a softening point temperature in the range of about 500 to about 1 claim 1 ,700° C.8. The glass composition of claim 1 , wherein a fused ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMIRA (Adalimumab). 1. A delamination resistant pharmaceutical container comprising a glass composition comprising:{'sub': '2', 'from about 70 mol. % to about 80 mol. % SiO;'}from about 3 mol. % to about 13 mol. % alkaline earth oxide;{'sub': 2', '3, 'X mol. % AlO; and'}{'sub': '2', 'Y mol. % alkali oxide, wherein the alkali oxide comprises NaO in an amount greater than about 8 mol. %, a ratio of Y:X is greater than 1, and the glass composition is free of boron and compounds of boron.'}2. The pharmaceutical container of claim 1 , wherein the SiOis present in an amount less than or equal to 78 mol. %.3. The pharmaceutical container of claim 1 , wherein an amount of the alkaline earth oxide is greater than or equal to about 4 mol. % and less than or equal to about 8 mol. %.4. The pharmaceutical container of claim 1 , wherein the alkaline earth oxide comprises MgO and CaO and a ratio (CaO (mol. %)/(CaO (mol. %)+MgO (mol. %))) is less than or equal to 0.5.5. The pharmaceutical container of claim 1 , wherein the alkaline earth oxide comprises from about 0.1 mol. % to less than or equal to about 1.0 mol. % CaO.6. The pharmaceutical container of claim 1 , wherein the alkaline earth oxide comprises from about 3 mol. % to about 7 mol. % MgO.7. The pharmaceutical container of claim 1 , wherein X is greater than or equal to about 2 mol. % and less than or equal to about 10 mol. %.8. The pharmaceutical container of claim 1 , wherein the alkali oxide comprises greater than or equal to about 9 mol. % NaO and ...

IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES

In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same. 1. An article of manufacture comprising a sealed container and a sterile dry microparticle composition contained within said sealed container , said microparticle composition comprising blank biodegradable microparticles that comprise a biodegradable polymer , wherein said sealed container is configured to allow for the introduction and removal of sterile fluid.2. The article of manufacture of claim 1 , wherein said sealed container comprises a septum.3. The article of manufacture of claim 1 , wherein said article of manufacture is gamma irradiated.4. The article of manufacture of claim 1 , wherein said biodegradable microparticles comprise poly(lactide-co-glycolide).5. The article of manufacture of claim 1 , wherein upon the addition of water in an amount such that the microparticle composition has a concentration of 25 mg/ml claim 1 , a suspension is formed in which the microparticles have a D(v claim 1 ,0.5) value that is between 0.5 and 5 μm.6. The article of manufacture of claim 1 , wherein said microparticle composition is a lyophilized microparticle composition.7. The article of manufacture of claim 6 , wherein said microparticle composition further comprises a cryoprotective agent.8. The article of manufacture of claim 1 , wherein said container is a single dose container comprising between 4 and 50 mg of said microparticles claim 1 , and 5 and 150 mg of one or more pharmaceutical excipients.9. The article of manufacture of claim 1 , wherein said microparticle composition comprises charged microparticles.10. The article of manufacture of claim 9 , wherein said charged microparticles comprise a charged species in addition to said ...

Wafer pocket

For the secure keeping of wafers 8 and for prevention of penetration and/or migration by an active ingredient present in the wafer 8 into the packaging material of a primary pack which serves to keep the wafer 8, and, furthermore, for the easy removal of the wafer 8 after the opening of the primary pack, a wafer sachet 1 as the primary pack is proposed, being formed by a layer construction of films, which comprises first and second sealing films 3, 4 which are connected to one another via at least one sealing region, so that between the first and second sealing films 3, 4 a cavity 7 is formed which is closed off to the outside and is suitable for receiving the wafer 8. In accordance with the invention, the layer construction further comprises at least one peeling film 2 which is connected to the first sealing film 3, which is intended for opening the wafer sachet 1, which is partly removable from the first sealing film 3 on opening of the wafer sachet 1, and which, when it is partly removed from the first sealing film 3, causes incisive tearing of the first sealing film 3 on further opening of the wafer sachet 1, so that the cavity 7 is opened to the outside.

Crushing Bags and Methods for Use and Manufacture

A pill crusher pouch is constructed of a flexible sheet material having an open top and an open bottom, wherein the open bottom is dimensionally smaller than the open top, forming a funnel-like internal pouch cavity, and a crease near the bottom of the pouch that allows a user to easily fold the pouch to form a temporary seal that prevents crushed pill product from dispensing through the open bottom until the user unfolds the pouch.

MEDICAMENT CARTRIDGES WITH NON-STANDARD DIMENSIONS

A method of closing the distal end of an ampoule is shown. The ampoule has a variable diameter head portion having a locating surface and an opening. A septum is positioned on the opening and secured to the head portion with a ferrule using a plunger. The plunger exerts a force in a proximal direction to press the ferrule on the head portion until the press causes the ferrule to contact the locating surface. Further, the ampoule for use in a cartridge for a drug delivery device has non-standard dimensions to provide a coding system to reduce the risk of a user dispensing the wrong medicament from the drug delivery device. 110-. (canceled)11. A method of closing the distal end of an ampoule comprisingproviding an ampoule having a variable diameter head portion having a locating surface and an opening;positioning a septum on the opening; andsecuring the septum to the head portion with a ferrule using a plunger, where the plunger exerts a force in a proximal direction to press the ferrule on the head portion until the press causes the ferrule to contact the locating surface.121. The method of claim further characterized in that a rolling plate exerts a force in a distal direction to crimp the ferrule to the head portion.13. An ampoule for containing a medicament comprising ,a constant diameter body;a neck portion; anda head portion located distally of the neck portion and having a variable, non-constant diameter.141212. The ampoule of wherein the head portion has a first diameter (D) and a second diameter (D) claim 13 , wherein the first diameter (D) is less than the second diameter (D).1512. The ampoule of wherein a diameter (D) of the neck portion is less than the first and second diameters (D claim 14 , D).16. A system of medicament cartridges comprising{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'a first cartridge comprising a first ampoule according to , the first cartridge containing a first medicament; and'}{'claim-ref': {'@idref': 'CLM-00014', 'claim 14 ...

Custom-pill compounding system with filler-free capability

A system and associated aspects thereof are disclosed regarding custom-compounding of drug products such as pills and polypills for particular patients, herein involving adaptations of “micro-dosing” technology to permit sufficiently small and precise amounts of drug substances or optionally formulations thereof to be controllably and automatably handled and dispensed so as to help create customized drug products that do not necessitate bulking or dilution of the drug substances.

SURFACE IMMOBILIZED CHAPERONES

A container containing a therapeutic protein, characterized in that chaperones molecules are bound by a molecular linker to an inner surface of the container. The linker being interposed between the surface and the chaperone. 1. A container containing a therapeutic protein , wherein chaperones molecules are bound by a molecular linker to an inner surface of said container , said linker being interposed between the surface and the chaperone.2. A container according to claim 1 , wherein said linker is pre-adsorbed on the device surface.3. A container according to claim 2 , wherein said linker is an unfolded protein.4. A container according to claim 3 , wherein said linker is the same molecule as said therapeutic protein.5. A container according to claim 4 , wherein said linker defines a mixed monolayer of therapeutic protein on the surface.6. A container according to claim 5 , wherein said monolayer has a thickness <5 nm.7. A container according to claim 1 , wherein the ratio chaperone: linker is between 1:1 and 1:6000 claim 1 , preferably 1:300.8. A container according to claim 1 , wherein said linker is therapeutic insulin.9. A container according to claim 1 , wherein the container comprises one of a syringe claim 1 , a cartridge claim 1 , a vial claim 1 , an ampoule claim 1 , a reservoir or other device or structure suitable for holding and containing a pharmaceutical compound.10. A method for coating the inner surface of a container with chaperones molecules claim 1 , wherein it comprises the steps of:filing the container with a solution containing a molecular linker;emptying the container after a time of pre-adsorption of said molecular linker;washing the inner surfaces of the container with a buffer;adding to said inner surfaces the chaperones molecules. The present invention is directed to a container for a pharmaceutical compound having a protein component.Proteins are now commonly used in medical fields, and represent more than half of developed drugs. ...

Device for Capsule Retrieval

A collection device for retrieving a medical capsule discharges from the anus of a patient is disclosed. Medical capsules have been widely used for monitoring and diagnostic purposes. The capsule has to be retrieved to obtain the on-board data or for reuse of the capsule. Accordingly, cost effective, easy-to-deploy, and comfortable-to-use collection devices are disclosed for retrieving the capsule. The capsule collection device for retrieving a capsule discharged from anus of a patient into a bowl comprises a capture device to capture the capsule and to pass feces discharged from the anus, and a wand to pick up the capsule. A collapsible capture device is also disclosure which comprises a flange to adapt to a rim of the bowl, a sifting piece to separate the capsule from the feces, and a collapsible side walls to couple the sifting piece to the capture opening of the flange. Furthermore, a wand having ejection capability for ejecting a picked capsule is disclosed. 1. A capsule stripping kit , comprising:a pick-up wand to pick up the capsule discharged from an anus of a patient, wherein a magnet is coupled to a tip end of the wand to provide holding force for the capsule to connect with the tip end of the wand;a container having an opening to allow the capsule to be moved into the container; andmeans for stripping off the capsule from the tip of the wand into the container.2. The capsule stripping kit of claim 1 , wherein the means for stripping off the capsule comprises a structured piece at the opening of the container claim 1 , wherein the structured piece comprises a first region wide enough for the capsule to pass through in at least one first orientation claim 1 , and a second region narrow enough for the capsule to be blocked by the structured piece from passing through in at least one second orientation.3. The capsule stripping kit of claim 1 , wherein the means for stripping off the capsule comprises a lid to cover the opening of the container claim 1 , and ...

MEDICAMENT DISPENSING MACHINE

The disclosed device increases the accommodation amount of blister packages and enables smooth dispensing even if a blister package is bent or similar. The device is provided with: a device body (), a storage container () which accommodates blister packages () in a stacked state, and a dispensing member () which can dispense the accommodated blister package (). The storage container () is provided with an outlet (), which is formed on the base at one end side thereof, and which is for ejecting the blister package (), and a biasing means () for biasing the accommodated blister packages () toward one end side. The dispensing member () is provided with a guide part () for guiding a side edge part of the blister packages (), and biases the blister packages () toward one end side of the storage container (). 1. A medicine dispensing device comprising: a storage container in which a plurality of blister packages in which medicines are separately packed are accommodated in a stacked state, and', 'a dispensing member movably provided at the device body, the dispensing member moving up to the storage container and dispensing the accommodated blister package, wherein the storage container includes:, 'a device body;'}an outlet formed at one end side for taking out the blister package; anda biasing means that biases the accommodated blister package towards one end side,wherein the dispensing member includes a guide part for guiding a side edge part of the blister package, wherein the blister package can be biased towards one end side of the storage container by the guide part.2. The medicine dispensing device according to claim 1 , wherein the dispensing member includes an elastic piece that is capable of biasing the blister package towards one end side of the storage container claim 1 , andwherein the guide part for guiding the side edge part of the blister package is provided at an end section of the elastic piece.3. The medicine dispensing device according to claim 1 , ...

Apparatus, system and method for detection and delivery of a medicinal dose

An apparatus is disclosed as part of a system for tracking and confirming delivery of a medicinal dose to a user. The apparatus includes a detector. The detector is secured to and communicatively coupled to the user and is capable of detecting a current flow through the user's body. The current flow is produced when the user makes contact with the apparatus. The apparatus includes at least two contact areas connected to a power source where a circuit and, hence, a current path is completed through the user's body as the user makes contact with the apparatus. The current flow is detected by the detector, which is coupled to the user. Also disclosed is an apparatus for tracking and confirming delivery of a medicinal dose to a user where the apparatus includes an acoustic detector. Upon loading the dose into a chamber an acoustic vibration is generated. The vibration is detected and correlated with a current flow that is produced when the user makes contact with the apparatus. The combined event of vibration detection and current flow detection confirms that the dose is loaded and the user is in contact with the apparatus and ready to receive the dose.

PROSTAGLANDIN-CONTAINING PRODUCT

A prostaglandin-containing product including an aqueous liquid preparation containing 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α, or an alkyl ester or salt thereof, and a resin container containing said aqueous liquid preparation, the resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate, wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1, thereby inhibiting a decrease of the content of the 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α or an alkyl ester or salt thereof, in the aqueous liquid preparation. 1. A prostaglandin-containing product comprising an aqueous liquid preparation containing 16-phenoxy-15-deoxy-15 ,15-difluoro-17 ,18 ,19 ,20-tetranorprostaglandin F2α , or an alkyl ester thereof , or a salt thereof , and a resin container containing said aqueous liquid preparation , said resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate , wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1 , thereby inhibiting a decrease of the content of the 16-phenoxy-15-deoxy-15 ,15-difluoro-17 ,18 ,19 ,20-tetranorprostaglandin F2α or an alkyl ester thereof , or a salt thereof in the aqueous liquid preparation.2. A method of inhibiting the decrease of the content of a prostaglandin derivative in an aqueous liquid preparation , comprising storing the aqueous liquid preparation , containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water , in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate.3. A resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate for storing an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water. This application is a continuation application ...

Lens Holder Method

An apparatus for safely retaining an eye implant lens for transport and access for inspection and use in which a holding apparatus has a chamber for holding a lens. In one embodiment the chamber has aligned transparent portions and a lens can be placed in alignment with the transparent portions to enable inspection. Also, a system including the apparatus and a bottle assembly that will hold the apparatus in the bottle. A method for holding an eye implant lens in which a lens is placed in the apparatus which can then be placed in a bottle assembly. 1. A method for transporting a lens of the type used for eye implantation comprising;providing a holder apparatus for a lens comprising:a case having a storage chamber adapted to contain a lens in a substantially fixed position;the case having spaced apart transparent portions located at opposite sides of the storage chamber, the transparent portions being substantially aligned such that when a lens is contained in the storage chamber the lens is optically accessible through the transparent portions;placing a lens on the storage chamber;connecting the connectable portions;whereby the lens is substantially aligned with the transparent portions throughwhich the lens is optically accessible.2. The method of wherein the storage chamber comprises a ledge on which the periphery of a lens can rest when installed in the storage chamber.3. The method of in which the storage chamber comprises a post extending from one side of the storage chamber centrally of its transparent portion into the storage chamber whereby the lens having a centrally located opening can be installed on the post through the opening and be aligned with the transparent portions.4. The method of said case comprising an upper case and a lower case and further comprising a connecting structure comprising;on one of the upper case or the lower case a pair of slots radially shaped with respect to a center point, and being substantially diametrically opposite;on the ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN (filgrastim), NEULASTA (pegfilgrastim), EPOGEN (epoetin alfa) or ENBREL (etanercept). 149-. (canceled)50. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 62 , between about 7 and about 10 claim 62 , between about 7 and about 9 claim 62 , or between about 7 and about 8.53. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is recombinant human granulocyte-colony stimulating factor claim 62 , or an analog thereof.54. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises NEUPOGEN (Filgrastim).55. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is PEGylated recombinant human granulocyte-colony stimulating factor claim 62 , or an analog thereof.56. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises NEULASTA (Pegfilgrastim).57. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is an erythropoiesis-stimulating glycoprotein.58. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LEVEMIR, NOVOLOG, NOVOLIN 70-30, NOVOLIN R, NOVOLIN N, NOVOLOG MIX 70-30 and NOVOLIN L. 149-. (canceled)50. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 63 , between about 7 and about 10 claim 63 , between about 7 and about 9 claim 63 , or between about 7 and about 8.53. The pharmaceutical container of claim 63 , wherein the active pharmaceutical ingredient is an insulin analog.54. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition is selected from the group consisting of LEVEMIR claim 63 , NOVOLOG claim 63 , NOVOLIN 70-30 claim 63 , NOVOLIN R claim 63 , NOVOLIN N claim 63 , NOVOLOG MIX 70-30 and NOVOLIN L.55. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition is LEVEMIR.56. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition is NOVOLOG.57. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition is NOVOLIN 70-30.58. The pharmaceutical container of claim 63 , wherein the pharmaceutical composition is NOVOLIN R.59. The pharmaceutical container of claim 63 , wherein the pharmaceutical ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PROCRIT (epoetin alfa), REMICADE (Infliximab) or DORIBAX (doripenem). 149-. (canceled)50. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 62 , between about 7 and about 10 claim 62 , between about 7 and about 9 claim 62 , or between about 7 and about 8.5349. The pharmaceutical container of claim claim 62 , wherein the active pharmaceutical ingredient is an erythropoiesis-stimulating glycoprotein.54. The pharmaceutical container of claim 53 , wherein the glycoprotein is epoetin alfa.55. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises PROCRIT (epoetin alfa).56. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is doripenem monohydrate.57. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises DORIBAX.58. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is an antibody specific for human tumor necrosis factor alpha.59. The pharmaceutical container of claim 58 , wherein the antibody is infliximab.60. The pharmaceutical container of claim 62 , wherein the ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LANTUS (insulin glargine [rDNA]), LOVENOX (Enoxaparin), PENTACT-HIB (type b polysaccharide conjugated to tetanus protein, diphtheria, tetanus, pertussis and inactivated poliovirus vaccines) or FLUZONE or VAXIGRIP (influenza virus vaccine). 149-. (canceled)50. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 62 , between about 7 and about 10 claim 62 , between about 7 and about 9 claim 62 , or between about 7 and about 8.53. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is insulin glargine [rDNA].54. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises LANTUS (insulin glargine [rDNA]).55. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is enoxaparin.56. The pharmaceutical container of claim 62 , wherein the pharmaceutical composition comprises LOVENOX.57. The pharmaceutical container of claim 62 , wherein the active pharmaceutical ingredient is a vaccine.58. The pharmaceutical container of claim 57 , wherein the vaccine is an influenza virus vaccine.59. The pharmaceutical container of claim 62 ...

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, RITUXAN (rituximab), AVASTIN (Bevacizumab), LUCENTIS (Ranibizumab) or HERCEPTIN (trastuzumab). 149-. (canceled)50. The pharmaceutical container of claim 66 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 66 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 66 , between about 7 and about 10 claim 66 , between about 7 and about 9 claim 66 , or between about 7 and about 8.53. The pharmaceutical container of claim 66 , wherein the active pharmaceutical ingredient is an antibody claim 66 , or antigen binding fragment thereof claim 66 , that binds CD20.54. The pharmaceutical container of claim 53 , wherein the antibody is Rituximab.55. The pharmaceutical container of claim 66 , wherein the pharmaceutical composition comprises RITUXAN.56. The pharmaceutical container of claim 66 , wherein the active pharmaceutical ingredient is an antibody claim 66 , or antigen binding fragment thereof claim 66 , that binds vascular endothelial growth factor (VEGF).57. The pharmaceutical container of claim 56 , wherein the antibody is bevacizumab.58. The pharmaceutical container of claim 66 , wherein the pharmaceutical composition comprises AVASTIN.59. The pharmaceutical container of claim 66 , wherein the active ...

Ultrasound Coupling Liquid and Container

This invention relates to a coupling liquid for ultrasound devices, preferably high intensity focused ultrasound (HIFU). The coupling liquid comprises a liquid aqueous solution of at least one hydrophilic polymer having an average molecular mass of between 30,000 and 70,000 and at least one alcohol with a carbon chain of 1 to 7 carbon atoms. Also disclosed is a container ( 10 ) for an ultrasound coupling liquid having a thin wall.

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMALOG (insulin lispro), HUMALOG MIX 75-25 (insulin lispro), HUMALOG MIX 50-50 (insulin lispro), HUMILIN 70-30 (insulin), HUMILIN N (insulin), HUMULIN R (insulin) or GEMZAR (gemcitabine). 149-. (canceled)50. The pharmaceutical container of claim 61 , wherein the pharmaceutical composition comprises a citrate or phosphate buffer.51. The pharmaceutical container of claim 50 , wherein the buffer is selected from the group consisting of sodium citrate claim 50 , SSC claim 50 , monosodium phosphate and disodium phosphate.52. The pharmaceutical container of claim 61 , wherein the pharmaceutical composition has a pH between about 7 and about 11 claim 61 , between about 7 and about 10 claim 61 , between about 7 and about 9 claim 61 , or between about 7 and about 8.53. The pharmaceutical container of claim 61 , wherein the active pharmaceutical ingredient is insulin or an analog thereof.54. The pharmaceutical container of claim 53 , wherein the insulin analog is insulin lispro.55. The pharmaceutical container of claim 61 , wherein the pharmaceutical composition is selected from the group consisting of HUMALOG MIX 75-25 (insulin lispro) claim 61 , HUMALOG MIX 50-50 (insulin lispro) claim 61 , HUMILIN 70-30 (insulin) claim 61 , HUMILIN N (insulin) claim 61 , and HUMULIN R (insulin).56. The pharmaceutical container of claim 61 , wherein the active pharmaceutical ingredient is a nucleoside analog.57. The pharmaceutical container of claim 56 , wherein the nucleoside analog is an analog of deoxycytidine.58. The ...

Customized polypills having high drug loads

Patient-specific polypills, or similar drug products with potential to benefit from reduced need for bulking agent and preferably having multiple active ingredients, producible via appropriately adapted “micro-dosing” technologies not requiring fluid-jet or like substrate and solvent dependent approaches, having less need for excipient, particularly filler, so that the products may contain a larger number of different drug substances having a lower overall number or amount of excipient materials and/or may contain drug substances having comparatively less need for formulation development or pre-production processing and/or may contain fewer potential causes of side effects.

DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient. 150-. (canceled)51. The pharmaceutical container of claim 137 , wherein the container comprises a vial claim 137 , cartridge claim 137 , syringe claim 137 , ampoule claim 137 , bottle claim 137 , flask claim 137 , or vacutainer.52. The pharmaceutical container of claim 137 , wherein the container is delamination resistant.53. The pharmaceutical container of claim 137 , wherein the container has a delamination factor of 1.54. The pharmaceutical container of claim 51 , further comprising a pharmaceutical composition comprising an active pharmaceutical ingredient.55. The pharmaceutical container of claim 54 , wherein the active pharmaceutical ingredient is selected from the group consisting of an antidiabetic claim 54 , an anti-neoplastic Mab claim 54 , an antirheumatic claim 54 , an antibacterial claim 54 , a cytostatic claim 54 , a vaccine claim 54 , an immunosuppressant claim 54 , an anti-fibrinolytic claim 54 , an eye preparation claim 54 , a MS therapeutic claim 54 , a bone calcium regulator claim 54 , an anti-coagulant claim 54 , an anti-psychotic claim 54 , an anti-metabolite claim 54 , a radiopharmaceutical claim 54 , an immunostimulant claim 54 , a cytotoxic antibiotic claim 54 , a cerebral and peripheral vasotherapeutic claim 54 , a muscoskeletal agent claim 54 , a nootropic claim 54 , a CNS drug claim 54 , a dermatological claim 54 , an angiotensin II antagonist claim 54 , a serelaxin claim 54 , an anti-spasmodic claim 54 , an anti-cholinergic claim 54 , an interferon claim 54 , an anti-anaemic claim 54 ...

Abuse Potential Reduction in Abusable Substance Dosage Form

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure. 133-. (canceled)34. A method for reducing potential for substance abuse from a skin-worn transdermal patch device containing residual amounts of an abusable substance of interest after removal from a user , the method comprising:contacting said transdermal patch device as removed from a user to an anti-abuse substance selected from the group consisting of co-soluble antagonists, irritants and combinations thereof so that the potential for abuse is reduced.35. A method as in wherein said anti-abuse substance includes an amount of an antagonist.36. A method as in wherein said anti-abuse substance includes an amount of an irritant.37. A method as in wherein said abusable substance is an opioid.38. A method as in wherein said opioid is fentanyl.39. A system for reducing potential for substance abuse from a skin-worn transdermal patch device containing residual amounts of abusable substance after administration to a user claim 37 , said system comprising:(a) a disposable container having an opening therein to receive a skin-worn patch device containing a residual amount of an abusable substance therein;(b) an anti-abuse layer containing an amount of an antiabuse substance selected from the group consisting of co-soluble antagonists, irritants and combinations thereof, said anti-abuse layer being disposed in said container in a manner such that a skin-worn patch device properly inserted into said container causes said abusable substance of said skin-worn patch device to contact said anti-abuse layer; and(c) a closure for closing said container containing a used skin-worn patch device.40. A system as in wherein said anti-abuse substance includes an amount of an irritant.41. A system ...

FUNCTIONAL PACKAGING FOR A MEDICAL DEVICE

The present invention relates to a packaging for a medical device comprising a casing adapted to at least partially receive and/or to accommodate the medical device featuring at least one user-driven function, wherein the casing comprises at least one functional element adapted to imitate the at least one function of the medical device. 110-. (canceled)11. Packaging for a medical device comprising a casing adapted to at least partially receive and/or to accommodate the medical device featuring at least one user-driven function , wherein the casing comprises at least one functional element adapted to simulate the at least one function of the medical device , wherein the user driven function element of the medical device is either to be dialled , rotated or depressed and the functional element comprises a similar or identical geometry and/or arrangement.12. Packaging according to claim 11 , wherein the functional element is operably engaged with a closure means of the casing claim 11 , granting access to the medical device only in response of a correct pre-defined handling of the functional element.13. Packaging according to claim 11 , wherein the functional element is adapted to impede an opening of the casing.14. Packaging according to claim 13 , wherein the functional element is detachably connected to the closure means of the casing.15. Packaging according to claim 14 , wherein the closure means comprises a thread intersected by a protruding portion of the functional element claim 14 , wherein the protruding portion extends in a groove traversing the thread at least in sections.16. Packaging according to claim 11 , wherein the geometry and/or dimensions of the functional element correspond to the geometry and/or dimensions of a respective functional element of the medical device.17. Packaging according to claim 11 , wherein a first and a second component of the casing and/or a first and second component of the closure means comprise a respective first and second ...

Medical waste system

A medical disposal system is disclosed that includes a generally upright body portion formed of a material that is amenable to disinfectant in the hospital environment and that has surfaces shaped for easy cleaning in the hospital environment. The system has at least two separate waste disposal portions. A first portion is for waste other than sharps and has an opening large enough to receive waste that is typically other than sharps in the hospital environment including disposable clothing The opening to the first waste portion has a metal detector and an indicator system for providing a notification when a metal item is unintentionally placed in the opening. A second waste portion is for waste sharps and includes a relatively rigid sharps container and a safety lid that precludes sharps from leaving the container through the sharps opening.

LIQUID MEDICATION DISPENSING MACHINE

Provided is a liquid medication dispensing machine that can shorten the time to supply a liquid medication to a prescription bottle. The liquid medication dispensing machine is a liquid medication dispensing machine supplying a liquid medication from a liquid medication bottle containing the liquid medication to a prescription bottle, including a liquid medication stirring unit that stirs the liquid medication in the liquid medication bottle, a bottle holding unit that holds a plurality of liquid medication bottles including a first bottle containing a liquid medication G and a second bottle containing a liquid medication B, and a control unit that controls operation of the liquid medication dispensing machine. The control unit operates the liquid medication stirring unit to stir liquid medication B while liquid medication G is supplied from the first bottle to the prescription bottle. 1. A liquid medication dispensing machine supplying a liquid medication from a liquid medication bottle said liquid medication to a prescription bottle , comprising:a liquid medication stirring unit that stirs said liquid medication in said liquid medication bottle;a bottle holding unit that holds a plurality of said liquid medication bottles including a first bottle containing a first liquid medication and a second bottle containing a second liquid medication; anda control unit that controls operation of said liquid medication dispensing machine, whereinsaid control unit operates said liquid medication stirring unit to stir said second liquid medication while said first liquid medication is supplied from said first bottle to said prescription bottle.2. The liquid medication dispensing machine according to claim 1 , wherein said control unit starts supplying said second liquid medication from said second bottle to said prescription bottle after supply of said first liquid medication to said prescription bottle is completed.3. The liquid medication dispensing machine according to claim ...

COMPACT INJECTION DEVICE

The present invention relates to a package for a container comprising a tubular barrel having open distal and proximal ends, the proximal end being sized and shaped to receive a plunger, and the distal end being sized and shaped to receive an injection needle, said package comprising a plunger rod for said container, a part of said plunger rod being shaped complementarily to at least a part of the external shape of said tubular barrel, and a tray connectable to said plunger rod, said tray and said plunger rod forming said package when they are connected to each other. The invention further relates to a drug delivery device comprising a container and such a package. 1. A package for a container comprising a tubular barrel having open distal and proximal ends , the proximal end being sized and shaped to receive a plunger , and the distal end being sized and shaped to receive an injection needle , said package comprising i) a plunger rod for said container , a part of said plunger rod being shaped complementarily to at least a part of the external shape of said tubular barrel , and ii) a tray connectable to said plunger rod , said tray and said plunger rod forming said package when they are connected to each other.2. A package according to claim 1 , wherein said plunger rod and said tray are connected to each other by a releasable connecting member.3. A package according to claim 2 , wherein at least part of said releasable connecting member is provided between said plunger rod and said tray.4. A package according to any one of claims claims 2 , wherein at least part of said releasable connecting means member is provided on said plunger rod and on said tray.5. A package according to claim 2 , wherein said releasable connecting member comprises a lock.6. A package according to claims 2 , wherein at least part of said releasable connecting member is provided on one of said plunger rod and tray.7. A package according to claim 3 , wherein said releasable connecting member ...

Container Closure Delivery System

The present invention relates to a container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step. 1. A container closure delivery system suitable for stable storage of a lyophilized pharmaceutical injectable product , wherein the lyophilized pharmaceutical injectable product is dissolved into a liquid diluent without the need for a reconstitution mixing step.2. The container closure delivery system of claim 1 , wherein the lyophilized pharmaceutical injectable product is a storage stable powder formulation of a pharmaceutical product.3. The container closure deliver system of claim 1 , wherein the reconstitution of the lyophilized pharmaceutical product is through rapid dissolution claim 1 , and further wherein claim 1 , the lyophilized pharmaceutical injectable product is dissolved upon contact with the liquid diluent.4. The container closure delivery system of claim 1 , wherein the lyophilized pharmaceutical injectable product comprises an active ingredient and a stabilizer.5. The lyophilized pharmaceutical injectable product of claim 4 , wherein the lyophilized pharmaceutical injectable product further includes at least one of the following: a bulking agent claim 4 , a surfactant and a buffer.6. The container closure delivery system of claim 4 , wherein the active ingredient is selected from a small molecule claim 4 , a vaccine claim 4 , live or attenuated cells claim 4 , an oligonucleotide claim 4 , DNA claim 4 , a peptide and a recombinant or naturally occurring ...

Bushing for receiving a dropper neck, and corresponding package and kit

A bushing for the preparation of a suspension or solution formed by mixing a first product with a second product, to allow a first bottle initially containing the first product to communicate with a second bottle initially containing the second product is provided.

Blood Sugar Management System

The present invention is a system for managing blood sugar levels while on the go. A roll of water soluble sugar thin-film is contained within a specialized dispensing container. A sliding button is disposed on one side of the dispenser and actuates dispensing of a single sugar strip and advancement of a counter. Each sugar strip contains a predetermined dose of dextrose or other sugar in a rapidly dissolving oral film. Thus, diabetics and persons experiencing a blood sugar imbalance can rapidly dispense a measured dose of sugar that dissolves in saliva. A counter on the side of the dispenser tracks the number of remaining sugar strips, thereby ensuring that users who rely on ready availability of sugar strips are aware of their remaining supply. 1) A portable blood sugar management system , comprising:a plurality of hydrophobic film sugar strips;a portable sugar strip dispenser having an exit slot, wherein said dispenser houses said sugar strips;an actuating mechanism operatively connected to said dispenser such that engagement of said actuator mechanism dispenses one of said sugar strips through said exit slot;a counter disposed on said dispenser and operatively connected to said actuating mechanism such that dispensation of one of said sugar strips via said actuating mechanism updates said counter to reflect a remaining supply of sugar strips within said dispenser.2) The system of claim 1 , wherein said plurality of sugar strips are connected in a roll.3) The system of claim 1 , wherein said sugar strips are constructed from an edible hydrophobic polymer and a sugar.4) The system of claim 3 , wherein said sugar is dextrose or sucrose.5) The system of claim 1 , wherein said actuating means is a button.6) The system of claim 1 , wherein said dispenser has an internally disposed protective flap claim 1 , which abuts and covers said exit slot when not in use.7) The system of claim 6 , wherein said protective flap is operatively connected to said actuating mechanism ...

CHILDPROOF HIGHLY-INERT PACKAGING FOR INDIVIDUALLY DOSED FILMS CONTAINING AN ACTIVE INGREDIENT

A childproof packaging for individual doses, in particular for preparations for administration in film form, wherein the packaging constitutes a bag produced by sealing, which has at least one each side a covering layer which is provided at least on one side with local weak points which do not touch the edge of the packaging, wherein the local weak points form a cohesive pattern which runs around the individual dos in an arc or a curve and overlaps an angular region of at least 90° when considered from the main area of the individual zone. 1. Childproof package for a single dose , in particular for film-shaped administration forms , wherein said package comprising a pouch which is produced by sealing and which at least on each side has a cover layer including on at least one face one or more local weaknesses that do not touch the edge of the package , wherein each of the local weaknesses form a continuous pattern that extends in an arc or in a curved path around the single dose and , viewed from the centre of gravity of the single dose , covers an angle range of at least 90°.2. Package according to claim 1 , wherein each of the local weaknesses extend at least for a large part in an unsealed area of the package claim 1 , which also includes the single dose claim 1 , and each of the local weaknesses is preferably a line of weakness.3. Package according to claim 1 , wherein the arc described by each of the local weaknesses has no corners or bending radii of less than 1 mm claim 1 , and has a tear diversion of preferably less than 9°.4. Package according to claim 1 , wherein the package additionally has at least one metal layer and claim 1 , preferably on the side facing the single dose claim 1 , additionally at least one sealing layer.5. Package according to claim 1 , wherein the package additionally has claim 1 , at a start area and/or an end area of each of the local weaknesses claim 1 , a sidecut claim 1 , which does not reach as far as the edge of the package ...

Preservation System for Consumables and Cosmetic Substances

Disclosed herein is preservation system for consumables and cosmetic substances. The preservation system obtains information about the consumables and cosmetic substance to be preserved, senses and measures the external environment to the preservation system, senses and measures the internal environment to the preservation system, senses and measures the state of the consumables and cosmetic substance, and stores such information throughout the period of preservation. Using this accumulated information, the preservation system can measure, or estimate, changes in efficacy content (usually degradation) during the period of preservation. Additionally, the preservation system can use this information to dynamically modify the preservation system to minimize detrimental changes to the efficacy content of the consumables and cosmetic substance, and in some cases actually improve the consumables and cosmetic substance attributes.

SKIN CARE AND RESTORATION COMPOSITION AND METHODS

Topical compositions, such as lip balms and other products for lip care, include combinations of ingredients that condition and heal the lips and skin. The topical compositions may be configured to remain in place on the lips or skin for relatively long periods of time. Methods of making topical compositions are also disclosed. 1. A topical composition , comprising beeswax , lanolin , shea butter , cocoa butter , castor oil , jojoba oil , avocado oil , flax seed oil , grape seed oil , aloe vera oil , meadowform oil , hemp oil , sea buckthorn , baobab oil , carrot seed oil , arnica oil , vitamin E oil , vitamin D oil , vitamin A oil , tea tree oil , balsam fir oil and green tea oil.2. The topical composition of claim 1 , having proportions substantially equal to a mixture that includes 1400 g of beeswax claim 1 , 400 g of lanolin claim 1 , 400 g of shea butter claim 1 , 400 g of cocoa butter claim 1 , 200 g of castor oil claim 1 , 200 g of jojoba oil claim 1 , 100 g of avocado oil claim 1 , 100 g of flax seed oil claim 1 , 50 g of grape seed oil claim 1 , 50 g of aloe vera oil claim 1 , 50 g of meadowform oil claim 1 , 50 g of hemp oil claim 1 , 50 g of sea buckthorn claim 1 , 50 g of baobab oil claim 1 , 25 g of carrot seed oil claim 1 , 25 g of arnica oil claim 1 , 50 claim 1 ,000 I.U. of vitamin E oil claim 1 , 50 claim 1 ,000 I.U. of vitamin D oil claim 1 , 50 claim 1 ,000 I.U. of vitamin A oil claim 1 , 15 g of tea tree oil claim 1 , 5 g of balsam fir oil and 10 g of green tea oil.3. The topical composition of claim 1 , having antiseptic claim 1 , antiviral claim 1 , antifungal claim 1 , anti-bacterial or anti-inflammatory properties.4. The topical composition of claim 1 , having antiseptic claim 1 , antiviral claim 1 , antifungal claim 1 , anti-bacterial and anti-inflammatory properties.5. The topical composition of claim 1 , consisting essentially of the beeswax claim 1 , the lanolin claim 1 , the shea butter claim 1 , the cocoa butter claim 1 , the castor oil ...

Propofol Formulations with Non-Reactive Container Closures

A container storing an anesthetic is disclosed. The container is sealed by a closure and stores a liquid anesthetic solution. The anesthetic is from 0.1% to 10% by weight of the liquid anesthetic solution. The container is made of a material that is inert to the anesthetic and the closure is made of siliconized rubber or a metal. A concentration of the anesthetic in a liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in a liquid anesthetic solution before the liquid anesthetic solution is stored in the container. 1. A container storing an anesthetic , comprising: the anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution,', 'the container being made of a material that is inert to the anesthetic, and', 'the closure being made of siliconized rubber or a metal, wherein, 'a container sealed by a closure and storing a liquid anesthetic solution,'}a concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container.2. The container of claim 1 , wherein the anesthetic is propofol.3. The container of claim 1 , wherein the container is selected from the group consisting of a vial claim 1 , a bottle claim 1 , a cartridge claim 1 , a syringe claim 1 , and a pre-filled syringe.4. The container of claim 1 , wherein the material that is inert to the anesthetic is glass.5. The container of claim 4 , wherein the glass is siliconized glass.6. The container of claim 1 , wherein the material that is inert to the anesthetic is plastic.7. The container of claim 1 , wherein the closure is selected from the group consisting of a stopper claim 1 , a plunger claim 1 , a lid claim 1 , and a top.8. The container of claim 1 , wherein the siliconized rubber is siliconized ...

DOUBLE-CHAMBER CONTAINER AND METHOD FOR MANUFACTURING SAME

There is provided a method for manufacturing a double-chamber container including an agent storage chamber and a solution storage chamber separated from each other by a weak seal portion, the method including the steps of: preparing a first sheet-like member including a first agent storage chamber forming portion and a first solution storage chamber forming portion whose one sides are joined to each other, as well as a second sheet-like member including a second agent storage chamber forming portion and a second solution storage chamber forming portion whose one sides are joined to each other; and forming the agent storage chamber and the solution storage chamber by joining the first and the second sheet-like members. The weak seal portion is formed by joining the one side of the first medical solution storage chamber forming portion and the one side of the second medical solution storage chamber forming portion. 1. A method for manufacturing a double-chamber container including a medical agent storage chamber and a medical solution storage chamber separated from each other by a weak seal portion , the method comprising the steps of:preparing a first sheet-like member including a first medical agent storage chamber forming portion and a first medical solution storage chamber forming portion whose one sides are joined to each other, as well as a second sheet-like member including a second medical agent storage chamber forming portion and a second medical solution storage chamber forming portion whose one sides are joined to each other; andforming said medical agent storage chamber and said medical solution storage chamber by joining said first sheet-like member and said second sheet-like member, whereinsaid medical agent storage chamber is formed by joining the other sides of said first medical agent storage chamber forming portion and the other sides of said second medical agent storage chamber forming portion,said medical solution storage chamber is formed by ...

PLACENTAL TISSUE GRAFTS

A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. 120-. (canceled)21. A dehydrated , laminated tissue graft consisting essentially of one or more washed and/or substantially cleaned amnion layers and one or more washed and/or substantially cleaned chorion layers that are directly assembled , laminated and dehydrated together.22. The tissue graft of claim 21 , wherein said assembled and laminated layers are dehydrated together in a drying fixture.23. The dehydrated claim 21 , laminated tissue graft of claim 21 , wherein one or both of the one or more amnion layers and the one or more chorion layers is treated with an antibiotic prior to lamination.24. The tissue graft of claim 21 , wherein the tissue graft has been exposed to sterilizing conditions.25. The tissue graft of claim 21 , consisting essentially of one amnion layer and one chorion layer.26. The tissue graft of claim 21 , consisting essentially of multiple amnion layers.27. The tissue graft of claim 21 , consisting essentially of multiple chorion layers.28. A dehydrated claim 21 , laminated tissue graft claim 21 , wherein the tissue graft ...

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Glass compositions with improved chemical and mechanical durability

The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO 2 ; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % Al 2 O 3 ; and Y mol. % alkali oxide. The alkali oxide may include Na 2 O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS

Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. 2. The compound of claim 1 , wherein Rand Rare hydrogen.3. The compound of claim 1 , wherein Ris hydrogen.4. (canceled)5. The compound of claim 1 , wherein Yis bond.6. The compound of claim 1 , wherein Ris CN.7. The compound of claim 1 , wherein Ris C(O)R.8. The compound of claim 1 , wherein Ris C(NH)NHOH.9. The compound of claim 1 , wherein Ris 5-tetrazolyl.10. The compound of claim 7 , wherein Ris OH.11. (canceled)12. The compound of claim 1 , wherein Ris hydrogen.13. The compound of claim 1 , wherein Xis substituted or unsubstituted C-Calkylene claim 1 , wherein the substituents when present are selected from one to four Qgroups claim 1 , where Qis alkyl or haloalkyl.14. (canceled)15. The compound of claim 1 , wherein A is substituted with from one to four Qgroups claim 1 , wherein Qis alkyl or haloalkyl.16. The compound of claim 1 , wherein Xis CH.17. The compound of claim 1 , wherein Xis O.18. The compound of claim 16 , wherein A is CHand q is 2.19. (canceled)20. The compound of claim 1 , wherein Ris F.2128-. (canceled)30. (canceled)31. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.32. A method for treating claim 1 , preventing or ameliorating a GSK-3 mediated disease comprising administering a compound of .33. The method of claim 32 , wherein the GSK-3 mediated disease is diabetes claim 32 , conditions associated with diabetes claim 32 , Alzheimer's disease claim 32 , Parkinson's disease claim 32 , progressive supranuclear palsy claim 32 , subacute sclerosing panencephalitic parkinsonism claim 32 , postencephalitic parkinsonism claim 32 , pugilistic encephalitis claim 32 , guam parkinsonism-dementia complex claim 32 , Pick's disease claim 32 , corticobasal degeneration ...

Medical Vial Access Device with Pressure Equalization and Closed Drug Transfer System and Method Utilizing Same

A vial access device includes a housing having first and second connectors. The first connector is configured to be secured to a first container and the second connector is configured to be secured to a second container. The vial access device further includes a spike member extending from the housing and having a proximal end and a distal end. The spike member defines a vent lumen and a fluid lumen spaced from the vent lumen with each of the vent lumen and the fluid lumen having a distal opening. A shape defined by a circumference of the spike member is only symmetric about one axis at a position between the proximal end of the spike member and the distal opening of the fluid lumen.

Container with child-resistant latching mechanism

A container and dispensing system is provided that includes a tamper resistant and sealable container with a child resistant latching mechanism. The container includes at least one hopper for storing a controlled substance or sensitive material, and includes a container unit locking lid with a locking mechanism that may be opened through manual manipulation or through the use of a key. In at least one embodiment, the locking mechanism is a flat spring locking device. A designated person, in the event of a pill container, a pharmacist, may control an optionally required key for removing the lid during refill operations. For other sensitive materials where tampering or unauthorized access is desired, such as a feed hopper, the owner of the container may retain control of the optional key.

MULTIFUNCTION MEDICINE CHEST

A multifunction medicine chest includes a chest, a door set at one side of the chest to open and close the chest and a control device. The chest is configured to store medicines and includes a plurality of drawers. Each drawer corresponds to one category of medicines. The control device includes an input unit, a storage unit, and a control unit. When a user stores a medicine into the chest, the input unit obtains medicine information of the medicine and transmits the medicine information to the control unit, the control unit determines the category of the medicine and a number of the drawer for the medicine and generates storage information of the medicine. When the user takes the medicine out of the chest, the input unit obtains portion medicine information of the medicine, the control unit searches for the storage information. 1. A multifunction medicine chest , comprising:a chest configured to store medicines, the chest comprising a plurality of drawers, each drawer corresponding to one category of medicines;a door for opening and closing the chest; anda control device mounted in the chest, the control device comprising an input unit, a storage unit, a display unit, and a control unit connected to the input unit, the storage unit, and the display unit; wherein when a user stores a medicine in the chest body, the input unit obtains medicine information of the medicine and transmits the medicine information to the control unit, the control unit determines the category of the medicine and a number of the drawer used to store the medicine and generates storage information which comprises the medicine information, the category, and the number of the drawer of the medicine, the control unit controls the storage unit to store the storage information and controls the display unit to display the storage information; when the user takes the medicine out of the chest, the input unit obtains portion medicine information of the medicine, the control unit searches for the ...

SOLID PHARMACEUTICAL COMPOSITION

The invention described herein pertains to a solid pharmaceutical composition comprising EC145 for reconstitution to provide a solution for intravenous injection, particularly to a lyophilized solid pharmaceutical composition comprising EC145 which has adequate stability for storage at ambient temperature and which is capable of redissolving in an aqueous diluent prior to administration, as well as a process for its manufacture, drug products comprising the composition and methods for using the composition for treating cancer. 1. A solid pharmaceutical composition comprising EC145 and a bulking agent.2. The composition of wherein:(a) the bulking agent comprises dextrose, glucose, glycine, inositol, mannitol, sorbitol, sucrose, a polyethyleneglycol (PEG), or a polyvinylpyrrolidine (PVP), or a combination thereof in an individual or combined range of about 3% to about 20% and/or arginine or proline in an individual or combined range of about 0.1 M to about 0.5 M; or(b) the bulking agent comprises dextrose, inositol, mannitol, sorbitol or sucrose, or a combination thereof, in an individual or combined range of about 3% to about 6% and/or arginine or proline in an individual or combined range of about 0.1 M to about 0.5 M; or(c) the bulking agent comprises about 3% to about 10% glycine or mannitol; or(d) the bulking agent comprises about 3% to about 4% mannitol and 0% to about 1% sucrose; or(e) the bulking agent comprises about 3% mannitol.3. The composition of comprising a further excipient.4. The composition of wherein the excipient comprises a buffer.5. The composition of wherein the buffer is an antioxidant which does not reduce a disulfide bond.6. The composition of wherein:(a) the pH of the buffer is about 5.0 to about 8.0; or(b) the pH of the buffer is about 5.7 to about 6.6; or(c) the pH of the buffer is about 6.0 to about 6.6; or(d) the pH of the buffer is about 6.2±0.2.7. The composition of wherein:(a) the buffer comprises an ascorbate, sorbate, formate, ...

CLOSED SYSTEM TRANSFER DEVICE AND AUTOMATION SYSTEM

A robotic intravenous automation system, including a robotically controlled holder configured to manipulate an intravenous (IV) bag and a closed system transfer device (CSTD). The controller includes a processor configured to control the holder. The IV bag includes a first fluid port and a second fluid port, and the CSTD includes a CSTD port, a spike adapter that is fluidically separated from the CSTD port, and a flexible member connecting the CSTD port to the spike adapter. 1. A robotic intravenous automation system , comprising:a robotically controlled holder configured to manipulate an intravenous (IV) bag and a closed system transfer device (CSTD) that form a CSTD IV bag assembly; anda controller including a processor configured to control the holder, whereinthe IV bag includes a first fluid port and a second fluid port,the CSTD includes a CSTD port, a spike adapter that is fluidically separated from the CSTD port, and a flexible member connecting the CSTD port to the spike adapter,the spike adapter is connected to the first fluid port of the IV bag, andthe CSTD port is connected to the second fluid port of the IV bag.2. The system according to claim 1 , wherein the controller is configured to perform a process of:accepting a user command to prepare an IV bag with a particular drug;determining whether the particular drug requires a CSTD;selecting, by the holder, the CSTD IV bag assembly based on the determining;attaching a CSTD syringe containing the particular drug to the CSTD port; andperforming a fluid transfer of the particular drug between the CSTD syringe and the IV bag via the CSTD port.3. The system according to claim 2 , wherein process further includes:outputting an indication to place the CSTD IV bag assembly into an inventory rack of the system; andverifying the CSTD IV bag assembly has been placed into the inventory rack of the system.4. The system according to claim 3 , wherein the verifying includes a visual-based verification by image analysis.5. ...

STORAGE APPARATUS WITH SUPPORT STRUCTURES

A storage apparatus is provided. The storage apparatus defines a storage cavity having an opening at the upper surface of the storage apparatus with a substantially planar flange extending outwardly from the opening of the storage cavity and defines a plurality of support structures, each support structure (a) having an opening at the upper surface of the storage apparatus and (b) adapted to support the storage apparatus. 1. A storage apparatus comprising an upper surface and a lower surface , the storage apparatus:defining a storage cavity having an opening at the upper surface of the storage apparatus with a substantially planar flange extending outwardly from the opening of the storage cavity; anddefining a plurality of support structures, each support structure (a) having an opening at the upper surface of the storage apparatus and (b) adapted to support the storage apparatus.2. The storage apparatus of claim 1 , wherein the storage apparatus is a blister package.3. The storage apparatus of claim 1 , wherein (a) the storage cavity comprises a medication cavity and (b) each support structure has a substantially rectangular cross section.4. The storage apparatus of claim 3 , wherein storage cavity is sized to accept a plurality of different types of medications of different shapes and sizes.5. The storage apparatus of claim 1 , wherein each support structure extends in a direction away from the opening of the storage cavity.6. The storage apparatus of claim 5 , wherein (a) the plurality of support structures comprises a first support structure and a second support structure and (b) the first support structure and the second support structure are positioned on opposite sides of storage cavity.7. The storage apparatus of further comprising a backing adhered to the substantially planar flange extending outwardly from the opening of the storage cavity claim 1 , thereby covering the opening of the storage cavity.8. The storage apparatus of claim 7 , wherein the backing ...

Medical rubber

The present invention provides a medical rubber having high cleanliness and excellent compression set resistance. The present invention relates to a medical rubber including an ethylene-propylene-diene rubber crosslinked by an organic peroxide having no aromatic ring structure.

Combination Container/Syringe

A combination container/syringe () provided with an outer cylinder () that forms a cylindrical shape centered on an axial line (O); a front stopper that is inserted into a distal end side of the outer cylinder (); and a cylindrical tip () that is fitted to an outer periphery of the distal end of the outer cylinder via a fitting hole () at a base end side, and that has a bypass chamber () that houses the front stopper at a front side of the fitting hole, in which an inner diameter of the bypass chamber is formed larger than an outer diameter of the front stopper, and a plurality of ribs () that protrude toward an inside in a radial direction and extend in the direction of the axial line to make close contact with the outer peripheral surface of the front stopper that has moved to the inside of the bypass chamber are provided spaced apart in a circumferential direction on the inner peripheral surface () of the bypass chamber. According to this combination container/syringe, it is possible to effectively eliminate air bubbles in a medicinal solution via a medicinal solution flow-through space that is formed over the circumferential direction between the inner peripheral surface of the bypass chamber and the outer peripheral surface of the front stopper. 1. A combination container/syringe comprising:an outer cylinder that forms a cylindrical shape extending along an axial line;a front stopper that is inserted into a distal end side of the outer cylinder;an end stopper that is inserted into a rear end side of the outer cylinder, and that seals a medicinal solution in a space with the front stopper;a cylindrical tip that is fitted to an outer periphery of the distal end of the outer cylinder via a fitting hole at a base end side, and that is provided with a bypass chamber that houses the front stopper at the distal end side of the fitting hole, and provided with a luer tip for attaching an injection needle;a finger grip that is fitted on the rear end side of the outer ...

CARTRIDGE FOR SURGICAL FASTENERS WITH INTEGRATED LOCK SYSTEM

A cartridge for holding surgical fasteners includes a base having a plurality of upstanding walls, adjacent pairs of walls defining spaces for holding surgical fasteners, at least one surgical fastener securing member movably connected to the base and movable relative to the base from an open position wherein fasteners can be loaded into the spaces, and a closed position wherein fasteners in the spaces are covered and held in the spaces, and a locking structure engageable between the base and the surgical fastener securing member for locking the surgical fastener securing member in the closed position. 1. A cartridge for holding surgical fasteners , comprising:a base having a plurality of upstanding walls, adjacent pairs of walls defining spaces for holding surgical fasteners;at least one surgical fastener securing member movably connected to the base and movable relative to the base from an open position wherein fasteners can be loaded into the spaces, and a closed position wherein fasteners in the spaces are covered and held in the spaces; anda locking structure engageable between the base and the surgical fastener securing member for locking the surgical fastener securing member in the closed position.2. The apparatus of claim 1 , wherein the surgical fastener securing member is pivotably connected to the base claim 1 , and pivotable relative to the base from the open position to the closed position.3. The apparatus of claim 1 , wherein the surgical fastener securing member has a sidewall portion connected to the base claim 1 , and a retaining member extending from the sidewall portion over at least a portion of one of the spaces when the surgical fastener securing member is in the closed position.4. The apparatus of claim 3 , wherein the sidewall is connected to the base by a living hinge which defines a pivot axis for movement of the surgical fastener securing member relative to the base.5. The apparatus of claim 4 , wherein the base and the sidewall are angled ...

CONTAINER WITH CONCENTRATED SUBSTANCE AND METHOD OF USING THE SAME

Apparatus and methods are described herein for a container with a unit dose of a concentrated substance that can be diluted and orally consumed using the container. In some embodiments, an apparatus includes a container body that defines an opening in fluid communication with an interior of the container body. A cap is coupled to the container body and encloses the opening. A unit dose of a concentrated medicament or a concentrated contrast agent is disposed within the interior of the container body. The unit dose of concentrated medicament or contrast agent can be diluted to a select dilution strength with a volume of a liquid receivable through the opening and within the interior of the container body. In some embodiments, the apparatus can include a barrier member in which the container body and cap can be disposed to protect the medicament or contrast agent from light and/or moisture. 1. A method , comprising:removing from an interior of a barrier member a container including a container body and a cap coupled to the container body, the container body having a unit dose of an excipient free concentrated contrast agent in powder form disposed within an interior of the container body, the barrier member configured to shield the unit dose of excipient free concentrated contrast agent from at least one of light or moisture;removing the cap from the container body;after the removing, adding a volume of a liquid to the interior of the container body such that the unit dose of the excipient free concentrated contrast agent is diluted to a select dilution strength; andafter the adding, providing the container body to a patient to orally consume the diluted excipient free concentrated contrast agent.2. The method of claim 1 , wherein the container body is provided to the patient prior to an imaging procedure to be performed on the patient.3. The method of claim 1 , further comprising:after the adding the volume of liquid, coupling the cap to the container body; ...

COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFOR

Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases. 1. A solid pharmaceutical composition comprising fusidic acid , or a pharmaceutically acceptable salt thereof , and mannitol.2. The pharmaceutical composition of wherein the w/w ratio of the fusidic acid or salt thereof to mannitol is in the range from about 1:1 to about 10:1.34.-. (canceled)5. A dosage unit comprising the solid pharmaceutical composition of claim 1 , where the fusidic acid or salt thereof is present in the range from about 275 mg to about 1 claim 1 ,000 mg.69.-. (canceled)10. The dosage unit of wherein the w/w ratio of the fusidic acid or salt thereof to mannitol is in the range from about 1:1 to about 10:1.1112.-. (canceled)13. The dosage unit of wherein the fusidic acid or salt thereof is present at about 10% to about 90% by weight.14. The dosage unit of wherein the fusidic acid or salt thereof is present at about 40% to about 60% by weight.15. A packaged article comprising a container and the pharmaceutical composition of wherein the pharmaceutical composition or the dosage unit is inside the container and wherein the container is an oxygen resistant and/or oxygen impermeable container.16. A packaged article comprising a container and the pharmaceutical composition of wherein the pharmaceutical composition or the dosage unit is inside the container and wherein the container or package includes an antioxidant compound or composition.17. A packaged article comprising a container and the pharmaceutical composition of wherein the pharmaceutical composition or the dosage ...

NEEDLE ASSEMBLY STORAGE DEVICE

Described is a needle assembly storage device comprising of a case having an opening, an array of needle assembly storage compartments disposed in the case, a transport mechanism coupled to a plurality of the needle assembly storage compartments, and a handle coupled to the case. When the handle is moved from a first position to a second position, the transport mechanism moves the plurality of the needle assembly storage compartments within the case to align a given one of the needle assembly storage compartments with the opening. 111-. (canceled)12. A needle assembly storage device comprising:a case having an opening;an array of needle assembly storage compartments disposed in the case;a transport mechanism coupled to a plurality of the needle assembly storage compartments;a handle coupled to the case, wherein when the handle is moved from a first position to a second position, the transport mechanism moves the plurality of the needle assembly storage compartments within the case to align a given one of the needle assembly storage compartments with the opening.13. The needle assembly storage device according to claim 12 , wherein the case comprises:a first portion detachably coupled to a second portion.14. The needle assembly storage device according claim 12 , wherein the handle is one of rotatably and hingedly mounted to the case.15. The needle assembly storage device according to claim 12 , wherein the handle includes a cover portion claim 12 , and when the handle is in the first position the cover portion covers the opening.16. The needle assembly storage device according to claim 12 , wherein the handle includes a hole claim 12 , and when the handle is in the second position the hole is aligned with the opening.17. The needle assembly storage device according to claim 12 , wherein the handle is biased in the first position.18. The needle assembly storage device according to claim 12 , wherein the transport mechanism includes:a transport wheel having at least ...

Red blood cell products and the storage of red blood cells in containers free of phthalate plasticizer

Red blood cell products and compositions are disclosed. The product includes a container made from PVC or a non-PVC material that is substantially free of a phthalate plasticizer but otherwise includes one or more non-phthalate plasticizers or extractable agents. The product includes a RBC concentrate which has been combined with an additive solution for storing the RBCs.

Gender specific pharmaceuticals

The present disclosure provides a system of gender specific pharmaceuticals. The system includes a first package of a pharmaceutical for use by a male and a second package of a pharmaceutical for use by a female. The first package includes a pharmaceutical for use by a male and a first label coupled to the first package, wherein at least one of the first package and first label includes a male specifier and a recommended male dosage. The second package includes a pharmaceutical for use by a female and a second label coupled to the second package, wherein at least one of the second package and second label includes a female specifier and a recommended female dosage.

Pressure-regulating vial adaptors

In certain embodiments, a vial adaptor comprises a housing configured to couple the adaptor with a vial, an access channel, a regulator channel, and a regulator assembly. The access channel is configured to facilitate withdrawal of fluid from the vial when the adaptor is coupled to the vial. The regulator channel is configured to facilitate a flow of a regulating fluid from the regulator assembly to compensate for changes in volume of a medical fluid in the vial. The regulator assembly can include a valve configured to transition between a closed configuration and an opened configuration.

PROPOFOL FORMULATIONS WITH NON-REACTIVE CONTAINER CLOSURES

A container storing a liquid anesthetic solution is disclosed. The container is sealed by a closure, and the liquid anesthetic solution includes an anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution, water, and a solvent. The container includes a material that is inert to the anesthetic, and the closure includes siliconized rubber, a fluoropolymer, or metal that is inert to the anesthetic. The concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container. 1. A liquid anesthetic solution stored in a container , comprising: an anesthetic being from 0.1% to 10% by weight of the liquid anesthetic solution,', 'water, and', the container comprises a material that is inert to the anesthetic, and', 'the closure comprises siliconized rubber, a fluoropolymer, or metal that is inert to the anesthetic, and', 'a concentration of the anesthetic in the liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in the liquid anesthetic solution before the liquid anesthetic solution is stored in the container., 'a solvent, wherein], 'a container storing the liquid anesthetic solution, the container being sealed by a closure, the liquid anesthetic solution comprising2. The liquid anesthetic solution stored in the container of claim 1 , wherein the anesthetic is propofol.3. The liquid anesthetic solution stored in the container of claim 1 , wherein the solvent is a water-immiscible solvent.4. The liquid anesthetic solution stored in the container of claim 3 , wherein the water-immiscible solvent is selected from the group consisting of soybean oil claim 3 , safflower oil claim 3 , cottonseed oil claim 3 , corn oil claim 3 , coconut oil claim 3 , sunflower oil ...

MULTI-LAYERED PLASTIC POLYMERIC CONTAINER FOR THE STORAGE OF PHARMACEUTICAL COMPOSITIONS

Multi-layered plastic polymeric container useful for the storage and conservation of pharmaceutical compositions, sterile or non sterile, which comprises an inner layer and an outer layer, a gas barrier layer, and adhesive layers. 1. Multi-layered plastic polymeric container for the storage of a composition comprising an inner layer and an outer layer in direct contact with the composition and the environment , respectively , a central gas barrier layer and two intermediate adhesive layers in between the central layer and the outer and inner polymeric layers , wherein the outer and inner layers comprise a mixture of polymers.2. Container of claim 1 , wherein polymers of outer and inner layers are polyolefins or polyesters.3. Container of any one of the and claim 1 , wherein polymers of outer and inner layers are polyolefins and polyolefins are chosen among polypropylene and/or polyethylene in the form of homopolymers or copolymers.43. Container of any one of - claims 1 , wherein the outer layer comprises a mixture of polymers and at least one branched polyolefin.54. Container of any one of - claims 1 , wherein the outer layer comprises a mixture of polymers and at least one branched polyolefin claims 1 , wherein the branched polyolefin in range of 5 to 25%.65. Container of any one of - claims 1 , wherein the outer layer comprises a mixture of polymers and at least one branched polyolefin claims 1 , wherein the branched polyolefin is present in a proportion of 20%.76. Container of any one of - claims 1 , wherein the outer layer comprises a mixture of polymers and at least one branched polyolefin claims 1 , and wherein the branched polyolefin is a polyalcene having 3 to 30 carbons claims 1 , and preferably between 5 to 15 carbons.87. Container of any one of - claims 1 , wherein the outer layer comprises a mixture of polymers and at least one branched polyolefin claims 1 , and wherein the branched polyolefin is a polyalcene which is present in a proportion of about 20 ...

Drug container

The present invention relates to an assembly comprising an injection device comprising a container for a product, wherein the container includes a distal tip encompassing a channel providing a passageway for transferring the product, and an adaptor mounted onto the distal tip. The assembly further includes a heat-shrinkable film covering at least part of the container and at least part of the adaptor, wherein the heat-shrinkable film maintains the adaptor blocked in rotation and in translation relative to the container when the heat-shrinkable film is in heat-shrunk condition.

Method For Reducing or Eliminating Residue in a Glass Container and a Glass Container made in Accordance Therewith

A method of preparing a glass medical container is provided including the steps of providing a glass blank and forming a channel through a part of the glass blank, the channel being substantially free of tungsten or derivatives thereof. In a further aspect of the subject invention, a glass medical container is provided including a glass body having a channel extending through a part of the glass body, the channel being substantially free of tungsten or derivatives thereof. With the subject invention, tungsten or derivatives thereof can be generally or altogether completely avoided in glass medical containers. 1. A method of producing a glass medical container , comprising the steps of:providing a glass bank;providing a pin at an opening in said glass bank; andforming said glass bank to conformingly engage said pin to form a channel,wherein said pin is made of a material that does not contain tungsten and which is selected from the group consisting of metals or alloys containing platinum or platinum group metals, metals or alloys containing nickel, silicides, and combinations thereof.2. The method of claim 1 , wherein said forming step comprises forming said glass bank to form a channel having a length and defining a diameter that is constant along said length.3. The method of claim 1 , wherein said forming step comprises forming said glass blank to form a channel having a length and defining a diameter that varies along said length.4. The method of claim 3 , wherein said forming step comprises forming said glass blank to form a channel having a first portion defining a first constant diameter and a second portion defining a second constant diameter claim 3 , said first diameter being larger than said second diameter.5. The method of claim 4 , wherein said first constant diameter is 0.6 mm and said second constant diameter is in the range of 0.2 to 0.4 mm.6. The method of claim 1 , wherein said glass medical container is selected from the group consisting of a ...

COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia. 2. A method of disrupting or inhibiting the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of tau fibrils and/or aggregates claim 1 , comprising administering a therapeutically effective amount of the compounds of .3. The method of claim 2 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.4. The method of claim 2 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.5. The method of claim 2 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day.6. A method resulting in neuroprotection from a tauopathy in a mammal comprising the step of administrating a therapeutically effective amount of a compound of .7. The method of where the tauopathy is one selected from; Alzheimer's disease claim 6 , Pick's disease claim 6 , progressive supranuclear palsy claim 6 , corticobasal degeneration claim 6 , familial frontotemporal dementia/Parkinsonism linked to chromosome 17 claim 6 , amyotrophic lateral sclerosis/Parkinsonism-dementia complex claim 6 , argyrophilic grain dementia claim 6 , dementia pugilistic claim 6 , diffuse neurofibrillary tangles with calcification claim 6 , progressive subcortical gliosis and tangle only dementia.8. An article of manufacture claim 1 , comprising packaging material claim 1 , the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , contained within packaging material claim 1 , which is used for treating ...

Temperature Detection Device, Temperature Detection Device Issuing Apparatus, and Temperature Detection Method

A temperature detection device, includes a base material and a temperature indicator, which is provided on the base material, which contains a reversible heat discoloration composition material having color change temperature hysteresis in a normal temperature environment, and which changes color when a detected temperature reaches a threshold value or lower.

Picking device and method for retrieving drug compositions from storage

A picking device for dispensing drug combinations arranged in storage vessels is provided. A storage device includes multiple storage locations for storage vessels, and an operating device is coupled to a controller. A stocking device moves storage vessels into the storage device, and an unloading device transfers drug combinations arranged in the storage vessels to a transport device.

Electrochemical Nitrogen Generator System and Method

An Electrochemical Nitrogen Generator System and Method. The system and method provide the ability to create a nitrogen-rich environment in containers of a variety of sizes. The system and method are able to extract the oxygen from the air within the container without reducing the internal pressure substantially below atmospheric. A version of the method is provided to reduce the oxygen content and replace it with nitrogen through a series of sequential fractional steps. In another form, the system and method will provide a “streaming” approach of bleeding off oxygen-containing contents of the container, while continuously replacing it with air until such time as the percentage of oxygen within the container is below the desired level. In yet another version, the system and method operate under pressure, thereby injecting pressurized air, either in sequential fractional steps or via continuous flow, whereby at the end of the process, the internal contents of the container are in a pressurized nitrogen environment, and the air expelled from the container during the process is also under pressure. 1. A method for removing oxygen from a container defined by an internal volume , comprising the steps of:filling the internal volume with a gas comprising a mixture of nitrogen and oxygen;sealing the container to enclose the internal volume;removing oxygen gas from the internal volume; andadding gas to the internal volume, wherein said gas comprises a mixture of nitrogen and oxygen.2. The method of claim 1 , wherein the pressure of said gas in the internal volume after said removing step is greater than or equal to 78 percent of the pressure of said gas in the internal volume before said removing step.3. The method of claim 2 , further comprising:a second removing oxygen step after said adding gas step, said second removing oxygen step comprising removing oxygen gas from the internal volume; anda second adding gas step after said second removing oxygen step, said second ...

RECYCLABLE FLEXIBLE POUCH AND METHODS OF PRODUCING AND USING SAME

A recyclable flexible pouch whose constituent parts can be easily deconstructed and placed into appropriate recycling streams. Recyclable flexible pouches having a product disposed therein are also disclosed, along with kits containing same. In addition, methods of producing the recyclable flexible pouches and packaged products are also disclosed. 1. A recyclable package for a product , the package comprising:a flexible pouch body defining a chamber into which a product may be disposed, the pouch body having a front wall and a rear wall each formed of a plurality of flexible layers of different materials so as to form at least an inner layer, an intermediate layer, and an outer layer united with one another, the union of the intermediate layer and the outer layer having a union strength less than the strength of the union between the intermediate layer and the inner layer such that the intermediate layer and the outer layer can be selectively peeled from the inner layer,wherein the pouch body has an opening defining a flow passage for dispensing the product into or from the pouch body.2. The package of claim 1 , wherein the intermediate layer and the outer layer are united with one another across at least a portion of their surface.3. The package of claim 1 , wherein the intermediate layer and the inner layer are united with one another across at least a portion of their surface.4. The package of claim 1 , further comprising a cap removably attached to the opening.5. The package of claim 1 , further comprising a first tear-line in the outer layer of the pouch body.6. The package of claim 1 , further comprising a first tear-line in the outer layer of the pouch body and a second tear-line in the intermediate layer of the pouch body.7. The package of claim 1 , further comprising a first tear-away strip integral with the outer layer of the pouch body.8. The package of claim 1 , further comprising a first tear-away strip integral with the outer layer of the pouch body ...

Ambroxol dry powder for inhalation use with bronchial target

The present invention relates to a preparation for inhalation use in form of dry powder comprising particles of ambroxol and/or hydrochlorides thereof, and at least a pharmaceutically acceptable excipient and/or dispersant wherein at least 85% of said particles has a geometrical diameter from 3 to 5 μm. The present invention further relates to the methods for preparing such composition and uses thereof. The present invention thanks to the very fine particles of dry powder, as above defined, constitutes a composition for inhalation use with optimum performances which, combined with inhaler action, reaches and acts directly on the bronchi or on the damaged respiratory tract. The local action and the quick absorption of the drug guarantee good features of bioavailability. The decrease in dosing Ambroxol with respect to the other existing oral or injectable formulations allows to reach quickly, locally and safely, the therapeutic target.

A SECONDARY PACKAGING FOR THERAPEUTIC PRODUCT

The invention describes a secondary packaging box for pharmaceutical products, comprising at least two separable compartments wherein the box comprises perforation to enable separation of the compartments. The box includes means for keeping the primary package stable and also detection of tampering owing to its design. 1) A secondary packaging box , for pharmaceutical products , comprising at least two separable compartments.2) The box according to claim 1 , wherein the box comprises perforation to enable separation of the compartments.3) The box according to claim 1 , wherein the box comprises perforations which may be in horizontal or vertical alignment.4) The box according to claim 1 , wherein the box is intended to hold the primary packaging claim 1 , including glass container or other breakable containers.5) The box according to claim 1 , wherein one compartment of the box is intended to hold the primary package containing a pharmaceutical product and other compartment/s may hold the primary package containing another or same pharmaceutical product or water solution for reconstitution of the pharmaceutical product.6) The box according to claim 1 , wherein the pharmaceutical product is a multi-dose pharmaceutical product.7) The pharmaceutical product according to claim 5 , is a lyophilized anti-HER 2 antibody.8) The box according to claim 1 , whereby owing to the separation of the compartments claim 1 , an additional surface is exposed which could be used to record information claim 1 , such as of the patient claim 1 , product claim 1 , dosage claim 1 , treatment details.9) The box according to claim 1 , wherein the interior of one or more compartments of the box comprises holder trays or flat trays and/or extended flaps to ensure stable holding of the primary packaging components claim 1 , and the pharmaceutical product contained therein and thus prevent any breakage and provides additional stability to the pack.10) The box according to claim 1 , owing to the ...

Biological Sample Containment System and Label

A biological sample containment system that includes a biological specimen collection container for collecting a biological sample and a label for the container is disclosed. In one embodiment, the label includes a first or front side and a second or rear side having a readable information portion. The label is affixable to the container by the second side and with the label affixed to the container, the readable information portion on the second side is readable through a portion of the container. By including readable information on the second or rear side of the label, the amount of readable information that can be included on the label is increased by using the previously unused rear side of the label. 1. A label for a container for collecting a biological sample , the label comprising:a first side; anda second side having a readable information portion, the label affixable to the container by the second side,wherein with the label affixed to the container, the readable information portion on the second side is readable through a portion of the container.2. The label of claim 1 , wherein the second side includes a first readable information portion and a second readable information portion above the first readable information portion claim 1 , wherein with the label affixed to the container claim 1 , at least one of the first readable information portion and the second readable information portion is readable through a portion of the container.3. The label of claim 2 , wherein at least a part of the first readable information portion is a fill line indicator and at least a part of the second readable information portion is a barcode.4. The label of claim 1 , wherein at least a part of the readable information portion is a fill line indicator.5. The label of claim 1 , wherein at least a part of the readable information portion is a barcode.6. The label of claim 1 , wherein at least a part of the readable information portion comprises electronically readable ...

COATED PACKAGING

A vessel has an interior surface facing a lumen. The interior surface includes a tie coating or layer, a barrier coating or layer, and a pH protective coating or layer. The tie coating or layer can comprise SiOCor SiNC, where x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3. The barrier coating or layer can comprise SiO, wherein x is from 1.5 to 2.9. The barrier coating or layer reduces the ingress of atmospheric gas into the lumen. The pH protective coating or layer can comprise SiOCor SiNC, as well. In an embodiment, in the presence of a fluid composition contained in the lumen and having a pH between 5 and 9, the calculated shelf life of the package can be more than six months at a storage temperature of 4° C.

SYSTEMS AND METHODS FOR MONITORING MEDICATION ADHERENCE AND COMPLIANCE

Systems and methods for monitoring medication adherence and compliance are provided. A medication monitoring system may include a medication container, a cover, and a beacon system. The beacon system may include a beacon that transmits a wireless signal when the cover is removed from the medication container. A method for monitoring medication adherence and compliance may include detecting when a cover of a medication container is removed from the medication container. The method may further include transmitting based on the detection, a signal from a beacon to a remote device, which indicates the opening of the medication container 1. A method comprising:receiving, by a computing device using a wireless receiver, a signal from a medication container, the medication container associated with an individual;determining, by the computing device, a medicine type based on the signal;determining, by the computing device, information associated with the medicine type and based at least in part on the individual; andoutputting, by the computing device, a notification based on the determined information associated with the medicine type.2. The method of claim 1 , further comprising:determining, by the computing device, the medicine type is a wrong medicine type based on prescription information; andwherein the notification comprises a notification indicating the medicine type is the wrong medicine type.3. The method of claim 1 , further comprising:determining one or more medication instructions corresponding to the medicine type; andwherein the notification comprises one or more of the one or more medication instructions.4. The method of claim 3 , wherein the one or more medication instructions comprises one or more of (i) medication instructions to take the medicine type with food or water claim 3 , (ii) medication instructions to not drink alcohol while taking the medicine type claim 3 , or (iii) medication instructions to not drive or operate heavy machinery after taking ...

A medical device container

To provide a medical device container, which enables transportation of a stored medical device in a fixed condition. A medical device container includes a container body having an opening portion at the upper portion; a holder, which is housed in the container body, for holding at least one medical device; and a gas non-permeable film sealing the opening portion of the medical device container; wherein the internal pressure of the medical device container is set to a value less than the atmospheric air pressure.

Tray for Handling Syringe Barrels

A handling system for use in the manufacture of syringe barrels includes a tray having an array of apertures with a tubular upstand around each aperture, each upstand at the upper end thereof defining a support surface for a syringe barrel. Each syringe barrel comprises a cylindrical part and an enlargement at or adjacent the rear end of the barrel and carries at its forward end a safe needle device or a needle shield of a greater diameter than the syringe barrel. At least one of the enlargement of the syringe barrel or the support surface has a profile tapering or rounded inwardly in the downward direction so that when the tray is supported generally horizontally and a syringe barrel is lowered into an upstand, the syringe barrel is centred by co-operation between the enlargement and the support surface. The enlargement may be a flange at the rear end of the syringe barrel or could be a further component fitted to the barrel. 1. The combination of a plurality of tubular syringe barrels each having an enlargement at or adjacent one end and a needle shield mounted at the other end thereof wherein the needle shield is of a greater diameter than the syringe barrel , and a handling system for the plurality syringe barrels , the handling system comprising a tray having an array of apertures therethrough each of a sufficient size for a syringe barrel and associated needle shield to pass therethrough and having a support surface configured for engagement by the enlargement of a syringe barrel received in the aperture when the tray is supported generally horizontally and the syringe barrel is lowered into an aperture , at least one of the part of the enlargement adjacent the syringe barrel and said support surface of an aperture having a profile configured to cause substantial concentric alignment of the enlargement within the aperture.2. The combination of claim 1 , wherein the enlargement of the syringe barrel is one of an integral formation with the syringe barrel or a ...

MEDICAL DEVICE PACKAGE

A package system for a medical device is disclosed. The package system may include a first part and a second part, where a holding platform can be incorporated into the first part of the package system and a collection tray can be incorporated into the second part of the package system. The first part may include leg portions. The leg portions of the first part can be folded and fitted into matching pockets of the second part, so that the first part of the package system can provided a relatively elevated and stable holding platform to hold the medical device. The package system can contain the medical device in the package system in a storage state, and hold the medical device with the holding platform in an application state. 1. A package system for a medical device , comprising:a first part; anda second part,wherein the first part includes a holding platform configured to receive and hold at least a portion of the medical device in an application state of the medical device,the second part includes contoured areas at least partially matching a profile of the medical device in a storage state of the medical device, andthe first part and the second part are configured to be assembled together in the application state so that the holding platform is at an elevated position relative to the second part.2. The package system of claim 1 , wherein the medical device is a vessel occlusive device.3. The package system of any of claim 1 , wherein the first part includes a first leg portion claim 1 , a middle portion and a second leg portion claim 1 , and the holding platform is integrated in the middle portion.4. The package system of any of claim 1 , wherein the first part further includes a first hinge between the first leg portion and the middle portion claim 1 , and a second hinge between the second leg portion and the middle portion.5. The package system of any of claim 3 , wherein the first leg portion and the second leg portion are foldable toward under the holding ...

Communication System And Method Implementing A Recipient For A Cosmetic Or Pharmaceutical Product Or A Wine Or A Spirit And Two Mobile Telecommunication Devices

The invention concerns the field of communicating objects intended to promote a smart environment. The invention more particularly concerns a communication system comprising:—a recipient for a cosmetic or pharmaceutical product or a wine or a spirit as the communicating object and—at least two mobile telecommunication devices The invention also concerns an associated communication method. The recipient is incorporated into the communication system in such way as to adapt at least to the presence of the first mobile telecommunication device in the coverage area of the communication means of same. The recipient is therefore advantageously an actor of the communication system. The recipient promotes the smart environment defined by the communication system. 1. A communication system , wherein the communication system comprises:a container for a cosmetic or pharmaceutical product or a wine or spirit, andat least two mobile telecommunication devices,wherein the container comprises a plurality of electronic components that are operatively interconnected, including:at least one source of sensory stimulation, arranged to emit a sensory signal towards the exterior of the container,two-way short-range radio communication means,control means for said at least one source of sensory stimulation, and wherein a first among said at least two mobile telecommunication devices comprises two-way short-range radio communication means,such that the container and a second among said at least two mobile telecommunication devices are able to communicate with each other via the first mobile telecommunication device, when the first mobile telecommunication device is located in a coverage area of the two-way communication means of the container,the control means of the container controlling said at least one source of sensory stimulation so as to generate a sensory signal sequence determined at least on the basis of data communicated to the container by the second among said at least two ...

SYSTEM FOR ADMINISTRATION OF CARDIAC PROTECTIVE THERAPY

An dosage member, comprising a planar member comprising a saliva-dissolvable member, a therapeutic agent carried in said planar member, wherein the saliva-dissolvable member is printed or color-coded to indicate potency. A plurality of aspirin containing dissolvable members may each be color-coded to indicate potency, and include a plurality of green dissolvable members and at least one dissolvable member with a color selected from the group consisting of yellow or amber, a red or red like color and a blue or blue like color. Perforations may provided so that higher potency strips may be divided into lower potency dosages. 1. An aspirin dosage member , comprising:(a) a planar member comprising a saliva-dissolvable member;(b) 60-325 mg of aspirin carried in said planar member.2. Aspirin dosage as in claim 1 , wherein the saliva-dissolvable member is printed or color-coded to indicate potency.3. A plurality of aspirin containing dissolvable members as in claim 2 , wherein saliva dissolvable members are each color-coded claim 2 , and including a plurality of green dissolvable members and at least one dissolvable member with a color selected from the group consisting of yellow or amber claim 2 , a red or red like color and a blue or blue like color.4. A plurality of aspirin containing dissolvable members as in claim 3 , wherein said green members have a potency of 40 to 120 mg of aspirin claim 3 , said yellow or amber members have a potency of 130 to 190 mg of aspirin and said red or red like members have a potency of 250 to 650 mg of aspirin claim 3 , and set blue members have a potency between 485 and 800 mg of aspirin.5. An dosage member claim 3 , comprising:(a) a planar member comprising a saliva-dissolvable member;(b) a therapeutic agent carried in said planar member, wherein the saliva-dissolvable member is printed or color-coded to indicate potency.6. A plurality of dosage members as in claim 5 , wherein said therapeutic agent is aspirin and said planar member is ...

PRODUCTION OF MIDBRAIN DOPAMINERGIC NEURONS AND METHODS FOR THE USE THEREOF

Methods are provided for efficient production of midbrain dopaminergic (DA) neurons. In some aspects, methods involve differentiation and selection of DA neurons for a transgenic pluripotent cell population (e.g., cells comprising a selectable marker gene). Cell populations produced by the instant methods and methods of their use are likewise provided. 144-. (canceled)45. A method for providing an enriched population of midbrain dopaminergic (DA) neurons comprising:differentiating cells of a population of human induced pluripotent cells to provide a neural lineage cell population;further differentiating cells of the neural lineage cell population to generate a cell population which includes midbrain neurons; andpurifying cells from said cell population using a transgenic screenable or selectable marker under the control of a pan-neural promoter expressed by cells of the cell population, to provide an enriched population of midbrain DA neurons;wherein the differentiation differentiation steps are carried out in a chemically defined medium that is free of feeder cells and feeder cell extracts and at least 80% of cells in the enriched population are positive for both Lmx1 and FoxA2 expression.46. The method of claim 45 , wherein the enriched population of midbrain dopaminergic (DA) neurons comprise mammalian midbrain dopaminergic (DA) neuronal cells claim 45 , at least about 85% the neuronal cells being positive for both LIM homeobox transcription factor 1 (Lmx1) and forkhead box A2 (FoxA2) expression.47. The method of claim 46 , wherein the neuronal cells comprise at least 500 claim 46 ,000 cells.48. The method of claim 47 , wherein the neuronal cells comprise at least 1 million cells.49. The method of claim 46 , wherein at least about 80% of cells in the enriched population are positive for TH expression.50. The method of claim 45 , wherein the pan-neural promoter is a TuJ-1 claim 45 , Map-2 claim 45 , Dcx claim 45 , Synapsin claim 45 , enolase 2 claim 45 , glial ...

Secure storage vessels and methods of using the same

The present disclosure provides secure storage containers, e.g., which may be used as a vessel to store and/or transport medication, controlled substances, and other materials.

Apparatus and methods for sealing a medicament within a medical delivery device

Apparatus and methods for lyophilizing and sealing a medicament within a medical delivery device having an opening. The apparatus may include a stopper for sealing the opening. The stopper may have one or more elongated members extending from a base, in a direction that is parallel to a central axis of the base. One or more of the members may be set radially away from the axis and define a coaxial central well. The member or members may define a void. The elongated member or members may engage a device inner wall and support the base away from the opening. The void may provide gas exchange between a device interior and a device exterior. The gas may be a lyophilization byproduct that escapes from the device interior between the inner wall, the base and the member or members. The stopper may be advanced into the device to seal the opening.

PACIFIER ASSEMBLY COMPRISING OUTER CONTAINER, WRISTBAND, AND TETHER

An assembly for a pacifier is provided. The assembly includes a container defining a cavity for housing a bulbous portion of a pacifier, a tether for coupling the container to the pacifier, a spool housed within the container for permitting translation of the pacifier in relation to the container, and a band extending through a slot defined by the container for selectively engaging the assembly to an object or person. Configurations are provided to manage rotation of the spool for ease of use. 1. An assembly comprising:a container defining a cavity for housing a bulbous portion of a pacifier;a tether for coupling the container to the pacifier;a spool housed within the container for permitting translation of the pacifier in relation to the container; anda band extending through a slot defined by the container for selectively engaging the assembly to an object or person.2. The assembly of claim 1 , wherein the assembly defines a stored position in which the pacifier is housed within the cavity of the container and an extended position in which the pacifier is a distance from the cavity of the container claim 1 , and wherein the assembly is biased to the stored position.3. The assembly of claim 2 , wherein the biasing is created using a spring engaged with the spool and an extension positioned within the container.4. The assembly of claim 1 , wherein the cavity defines a divot shaped for accepting the bulbous portion and an open side opposite the divot for permitting translation of the pacifier in relation to the container.5. The assembly of claim 1 , further comprising a ring affixed to the tether and selectively engaged with the pacifier.6. The assembly of claim 5 , wherein the ring and the container each include at least one magnet for selectively engaging the ring to the container.7. The assembly of claim 1 , further including the pacifier.8. The assembly of claim 1 , wherein the band is flexible and includes spring bands therein for conforming about an object or ...

Low-boron zirconium-free neutral glass having an optimized alkali metal ratio

A zirconium-free neutral glass is provided that finds use in the pharmaceutical sector. The glass has a combination of alkali metal oxides of sodium, potassium and optionally lithium, and a controlled amount of aluminium oxide, which provides a zirconium-free and low-boron neutral glass having good hydrolytic stability, good acid and alkali stability and good devitrification properties. The glass includes the following components in % by weight: 2. The neutral glass according to claim 1 , wherein the SiOhas a content in a range from 75% to 81% by weight.3. The neutral glass according to claim 1 , wherein the SiOhas a content in a range from 77% to 80% by weight.4. The neutral glass according to claim 1 , wherein the BOhas a content in a range of 3%-6.5% by weight.5. The neutral glass according to claim 1 , wherein the BOhas a content in a range of 3.5%-5.5% by weight.6. The neutral glass according to claim 1 , wherein the AlOhas a content in a range from 5% to 7.5% by weight.7. The neutral glass according to claim 1 , wherein the components do not contain any BaO.8. The neutral glass according to claim 1 , wherein the NaO has a content in a range of 2.8%-4.8% by weight.9. The neutral glass according to claim 1 , wherein the KO has a content in a range of 4%-8% by weight.10. The neutral glass according to claim 1 , wherein the KO has a content in a range of 4.2%-7.8% by weight.11. The neutral glass according to claim 1 , comprising 3.5% by weight of NaO and 6.5% by weight of KO.12. The neutral glass according to claim 1 , wherein the LiOhas a content in a range of 0%-0.5% by weight.13. The neutral glass according to claim 1 , further comprising a sum total of alkali metal oxides in a range between 6.8% and 13.3% by weight.14. The neutral glass according to claim 1 , further comprising a sum total of alkali metal oxides in a range between 7.0% and 12.6% by weight.15. The neutral glass according to claim 1 , wherein the KO/NaO ratio is in a range from 0.8 to 2.9.16. ...

Method & System of Customizing Dispensing of Pharmaceuticals

A closure system includes a non-child resistant cap configured to screw on and off a container in a non-child resistant mode. The system further includes a child resistant element configured to be able to be assembled with the non-child resistant cap to convert the non-child resistant cap to a child resistant cap permitting a push-down-and-turn action to remove the child resistant cap from a container. A child proof element is separate from the child resistant element is configured to be able to be assembled with the non-child resistant cap to convert the non-child resistant cap to a child proof cap requiring a key to remove the child proof cap from a container. 1. A method of customizing the dispensing of a prescription pharmaceutical for a customer in a pharmaceutical container , the method comprising the steps of: a non-child resistant cap configured to screw on and off the container in a non-child resistant mode to allow ready removal of the closure system when only the non-child resistant cap is installed on the container,', 'a child resistant element that is separate from the non-child resistant cap and is configured so as to be able to be assembled with the non-child resistant cap to convert the non-child resistant cap to a child resistant cap, wherein the child resistant element when assembled with the non-child resistant cap in a child resistant mode is configured to permit removal of the assembled child resistant cap upon a push-down-and-turn action being applied to the child resistant element when the assembled child resistant cap is installed on the container, and', 'a child proof element that is separate from the child resistant element and the non-child resistant cap and is configured so as to be able to be assembled with the non-child resistant cap to convert the non-child resistant cap to a child proof cap, wherein the child proof element when assembled with the non-child resistant cap in a child proof mode is configured to require a key to remove ...

METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound. 1. A method of killing breast cancer cells comprising administering to a breast cancer patient an effective amount of a combination of anti-cancer compounds , wherein the breast cancer cells do not express detectable levels of estrogen receptor alpha , and wherein the anticancer compounds comprise a glucocorticoid receptor antagonist and a chemotherapeutic.2. The method of claim 1 , wherein the breast cancer cells were previously administered a first chemotherapeutic more than two weeks prior to the combination of anti-cancer compounds.3. The method of claim 2 , wherein the breast cancer cells that were previously administered a first chemotherapeutic are chemo-resistant.4. The method of claim 3 , wherein the breast cancer cells are determined not to be chemo-sensitive or are determined to be chemo-resistant.5. The method of claim 1 , wherein the breast cancer cells are glucocorticoid receptor-positive (GR+).6. The method of claim 1 , wherein the patient is determined to have breast cancer cells that are GR+.7. The method of claim 1 , wherein the combination of anti-cancer compounds is administered within 1 week of each anti-cancer compound.8. The method of claim 7 , wherein the combination of anti-cancer compounds is administered within 24 hours of each anti-cancer compound.9. The method of claim 7 , wherein the glucocorticoid receptor antagonist is administered prior to the chemotherapeutic.10. The method of claim 9 , wherein the glucocorticoid receptor antagonist is administered up to three days prior to administering the chemotherapeutic.11. The method of claim 7 , wherein the glucocorticoid receptor ...

COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFOR

Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases. 1. A solid pharmaceutical composition comprising fusidic acid , or a pharmaceutically acceptable salt thereof , and mannitol.261.-. (canceled) This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 61/489,017 filed May 23, 2011. The entire disclosure of which is incorporated herein by reference.The invention described herein pertains to solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof. The invention described herein also pertains to solid pharmaceutical compositions and packages that may enhance stability to the degradation of the fusidic acid, or pharmaceutically acceptable salt thereof. The invention described herein also pertains to uses of the pharmaceutical compositions and dosage units in treating diseases.Fusidic acid is a tetracyclic triterpenoid or fusidane antibiotic derived from the fungus that inhibits bacterial protein synthesis. Fusidic Acid has the following structure.The term fusidic acid is also often used to denote not only fusidic acid, but also its pharmaceutically acceptable salts, such as the sodium salt, sodium fusidate, as well as hydrates, solvates or mixtures thereof, any of which may be considered the fusidic acid component. Accordingly, as used herein, the term fusidic acid generally refers individually and ...

DESICCANT CONTAINER WITH MOISTURE-INDICATING ABILITY

A desiccant container with moisture-indicating ability includes an inner container body, a container body, a cover member and a plurality of dry discoloration elements. The inner container body is to store a plurality of biological test pieces. The container body includes an accommodation portion to accommodate the inner container body, and a moisture-indicating portion is formed between the inner container body and the container body. The cover member engages exteriorly the container body. The dry discoloration elements, disposed in the moisture-indicating portion, are used to absorb moisture and then discolor. At least one of the inner container body and the container body is formed as a peeping structure made of a transparent material for inspecting coloring of the dry discoloration elements in the moisture-indicating portion. 1. A desiccant container with moisture-indicating ability , comprising:an inner container body for storing a plurality of biological test pieces;a container body, including an accommodation portion to accommodate the inner container body, a moisture-indicating portion being formed between the inner container body and the container body;a cover member, engaging exteriorly the container body; anda plurality of dry discoloration elements, disposed in the moisture-indicating portion, each of the plurality of dry discoloration elements being used to absorb moisture and then discolor, at least one of the inner container body and the container body being formed as a peeping structure made of a transparent material for inspecting coloring of each of the plurality of dry discoloration elements in the moisture-indicating portion.2. The desiccant container with moisture-indicating ability of claim 1 , wherein the accommodation portion of the container body is formed as a non-translucent structure made of a non-translucent material claim 1 , and the inner container body is formed as another non-translucent structure made of another non-translucent ...

Medicine Bottle

A medicine bottle is provided. The medicine bottle can have a bottle body, which has an inner space to receive a medicine, and a bottle top attached to the bottle body. The bottle top can have a riser tube, which projects into the inner space in order to facilitate a pumping of the medicine out of the inner space through the riser tube and out of the medicine bottle. The inner space can be delimited by a bottom side, of which the height varies over a base area of the bottle body between a maximum height and a minimum height, to allow the medicine to accumulate in the region of the minimum height in the case of a low fill level of the medicine. Additionally, a length of the riser tube can be chosen such that the riser tube projects further into the inner space than to the maximum height of the bottom side. 1. A medicine bottle ,having a bottle body which has an inner space to receive a medicine, and having a bottle top which is attached to the bottle body,wherein the bottle top has a riser tube which projects into the inner space in order to facilitate a pumping of the medicine out of the inner space through the riser tube and out of the medicine bottle, whereinthe inner space is delimited by a bottom side, of which the height varies over a base area of the bottle body between a maximum height and a minimum height to allow the medicine to accumulate in the region of the minimum height in the case of a low fill level of the medicine, anda length of the riser tube is chosen such that the riser tube projects further into the inner space than to the maximum height of the bottom side.2. The medicine bottle of claim 1 , whereinthe length of the riser tube is selected so that it extends as far as the minimum height of the bottom side.3. The medicine bottle according to of claim 1 , whereinthe length of the riser tube is at least as long as a connecting straight line from an upper end of the riser tube to the region of the bottom side with the minimum height.4. The medicine ...

CONTAINER-LOCATED INFORMATION TRANSFER MODULE

Techniques are described herein that transfer information using a container-located module. The module is coupled to sensor(s) that are configured to detect characteristic(s) pertaining to a medical substance that is included in a medical container. The module wirelessly transfers information that is based on the characteristic(s) to a requesting device in response to a request from the requesting device. 1. A system comprising:a supporting structure of a medical container, the supporting structure having an interior surface that defines an interior volume configured to contain a medical substance; and at least one sensor that is configured to detect one or more characteristics pertaining to the medical substance; and', 'a near field communication device that is coupled to the at least one sensor and that is configured to wirelessly transfer information, which is based on at least one of the one or more characteristics, to a near field reader in accordance with a near field communication protocol in response to receipt of a wireless request signal from the near field reader., 'a package being positioned on the interior surface, the package comprising'}2. The system of claim 1 , wherein the at least one sensor comprises:a microfluidics sensor configured to detect a chemical composition of the medical substance.3. The system of claim 1 , wherein the at least one sensor comprises:a first sensor configured to detect whether the medical substance is exposed to ambient air within the interior volume.4. The system of claim 1 , wherein the at least one sensor comprises:at least one microelectromechanical systems (MEMS) sensor; and 'a semiconductor package that includes at least a first layer and a second layer, the first layer including the at least one MEMS sensor and the second layer including the near field communication device.', 'wherein the system comprises5. The system of claim 1 , wherein the at least one sensor comprises:a first sensor configured to change from a ...

XANTHINE OXIDASE INHIBITOR FORMULATIONS

Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels. 1. A composition comprising a xanthine oxidase inhibitor , and an organic base , and optionally a pharmaceutically acceptable carrier.2. The composition of claim 1 , wherein said composition is in liquid form.3. The composition of claim 1 , further comprising bicarbonate or carbonate or salts thereof.4. The composition of claim 1 , further comprising an artificial or natural sweetening agent.5. The composition of claim 1 , further comprising a coloring agent.6. The composition of claim 1 , wherein said organic base is a basic amino acid.7. The composition of claim 6 , wherein the basic amino acid is choline claim 6 , lysine claim 6 , arginine or ornithine.8. The composition of claim 1 , further comprising an antioxidant.9. The composition of claim 1 , further comprising a vitamin.10. The composition of claim 9 , wherein said vitamin is C claim 9 , B1 claim 9 ,6 claim 9 ,12 claim 9 , or D.11. The composition of claim 9 , wherein said vitamin is not niacin.12. The composition of further comprising methyl cellulose.13. The composition of claim 12 , wherein said methyl cellulose is present at between 0.1 to 3 percent claim 12 , by weight.14. An article of manufacture comprising a container containing the composition of .15. The article of claim 14 , wherein said container is a bottle.16. The article of claim 15 , wherein said bottle is colored or masked to reduce io degradation of the xanthine oxidase inhibitor by electromagnetic radiation.17. The article of claim 15 , wherein the bottle is amber colored or translucent.18. A liquid formulation claim 15 , said formulation comprising a xanthine oxidase inhibitor claim 15 , and two or more of the ...

Secure Storage Device

A secure storage device for storing material is provided. The storage device includes a container having a void for external access to the interior space. A closure, similarly dimensioned according to the void may be joined to the container and can be manipulated between an open or closed state. An air evacuation system is also provided including an pressure release valve, a pressure indicator, and a pressure control system, such as a pump, for providing pressure to move air through a fluid communication channel from the interior space to the exterior of the container. 1. A storage device for securely storing material , the secure storage device comprising:a container having an enclosure about an interior space, wherein the container has a void for external access to the interior space;a closure similarly dimensioned to the void, wherein the closure is removable and is joined to the container at the void in one of an open or closed state;a pressure control system to remove air from the interior space through to the exterior of the storage device;a lock, wherein the lock conditionally restricts a change in state via an access control system, wherein the access control system is configured to present an input and conditionally allow the lock to change state.2. The storage device according to claim 1 , wherein the lock is a friction lock.3. The storage device according to claim 1 , wherein the lock is a mechanical lock.4. The storage device according to claim 1 , wherein the access control system and lock comprise a key lock for receipt of a corresponding key as input.5. The storage device according to claim 1 , wherein the access control system and lock comprise a combination lock for receipt of manipulated dials corresponding to alphanumeric input.6. The storage device according to further comprising an electronic port for receipt of electronic signal as input.7. The storage device according to claim 1 , wherein the lock further comprises a wireless device for ...

STORAGE CONTAINERS FOR VAPORIZER CARTRIDGES

A storage container and methods for releasably containing one or more vaporizer cartridges are provided. In an exemplary embodiment, the storage container can include a container cap that can be releasably secured to a container base thereby forming a storage volume configured to contain at least one vaporizer cartridge. In some embodiments, the storage container can include a cradle for positioning the vaporizer cartridge within the storage volume, such as for positioning the vaporizer cartridge relative to a transparent window along the container base. Various embodiments and features of the storage container are disclosed herein. 1. A storage container , comprising:a container base including a storage region defined by a base sidewall extending from a base plate, the base sidewall including a first coupling feature;a cradle positioned within the storage region for releasably securing an item within the storage region; anda container cap including an inner cap region defined by a cap sidewall extending from a cap top, the cap sidewall including a second coupling feature that releasably couples to the first coupling feature to thereby releasably couple the container cap to the container base.2. A storage container as in claim 1 , wherein the item is a vaporizer cartridge having a reservoir for storing a vaporizable material and an interface for coupling to a vaporizer device.3. A storage container as in claim 1 , wherein the first coupling feature includes a first cap interlock that engages a first base interlock of the second coupling feature when the container cap is secured to the container base claim 1 , the first cap interlock being prevented from disengaging the first base interlock before a first force is applied to the storage container.4. A storage container as in claim 3 , wherein the first coupling feature includes a second cap interlock that releasably engages a second base interlock of the second coupling feature when the container cap is secured to ...

MULTI-COMPARTMENT CONTAINER FOR THE SECURE STORAGE OF THERAPEUTIC AGENTS

A multi-compartment container for the secure storage of therapeutic agents comprises at least a base portion having at least two cavities, said at least two cavities serving as the location where said therapeutic agents are stored, and a child resistant device. Said child resistant device allows for the secure storage of said therapeutic agents. Said child resistant device may be in the form of a typical prescription pill container cap or may be more complex, such as a combination lock. Other features may include covers to keep said therapeutic agents in place, hinges to open said multi-compartment container, and labels corresponding to related cycles for said therapeutic agents. 1. A container for storing therapeutic agents , comprising:a lower portion having one or more lower cavities for storing said therapeutic agents;an upper portion having one or more upper cavities for storing said therapeutic agents; anda child resistant mechanism, such that said therapeutic agents stored in said lower portion and said upper portion are secured from tampering.2. The container of claim 1 , wherein said container further comprises at least one hinge connecting said lower portion and said upper portion.3. The container of claim 1 , wherein said container further comprises one or more lower walls in said lower portion claim 1 , wherein said one or more lower walls is placed such that said one or more lower walls create said one or more lower cavities.4. The container of claim 3 , wherein said container further comprises one or more upper walls in said upper portion claim 3 , wherein said one or more upper walls is placed such that said one or more upper walls create said one or more upper cavities.5. The container of claim 1 , wherein said container further comprises one or more lower portion covers claim 1 , placed upon and releasably attached to said lower portion such that said therapeutic agents within said one or more lower cavities are secured within said one or more lower ...

APPARATUS AND METHOD FOR DISPENSING AND RECEIVING MEDICAL SELF-COLLECTION DEVICES

The invention provides an apparatus for dispensing and otherwise facilitating the self-collection of biological medical samples. The apparatus is configured to dispense a medical self-collection device to a user and to hold or store a used medical self-collection device that has been deposited into the apparatus by a user for laboratory analysis. 1. An apparatus for dispensing and receiving a medical self-collection device , the apparatus comprising:an inner compartment;a housing surrounding the inner compartment;a user interface positioned on the housing and configured to accept information from a user;a means of dispensing the medical self-collection device; anda means of receiving a used medical self-collection device.2. The apparatus of further comprising payment collection unit in communication with the user interface and configured to collect payment from the user.3. The apparatus of further comprising a reservoir located within the inner compartment for holding unused medical self-collection devices.4. The apparatus of further comprising a covered output opening positioned on the housing and being operatively connected to the reservoir and configured to dispense an unused medical self-collection device to the user.5. The apparatus of further comprising a covered input opening for accepting a used medical self-collection device from the user.6. The apparatus of further comprising a collection receptacle located within the inner compartment being operatively connected to the covered input opening for holding used medical self-collection devices.7. The apparatus of wherein the used medical self-collection device is labeled with the information entered by the user on the user interface.8. The apparatus of wherein there is a means for adjusting the temperature in the reservoir.9. The apparatus of wherein there is a means for adjusting the temperature in the collection receptacle.10. An apparatus for dispensing and receiving a medical self-collection device claim 6 ...

PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME

This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived. 1. A composition comprising at least one vasoactive intestinal peptide (VIP) analog comprising HSDAVFTDNYTRLRKQMAVKKYLNSILN wherein at least three amino acids of SEQ ID NO:1 are replaced with a cyclic beta-3 amino acids and wherein the analog comprises an amino acid sequence that selectively binds to VIP Receptor 1.25.-. (canceled)6. The composition of claim 1 , wherein the analog is derived from a human VIP amino acid sequence.713.-. (canceled)14. The composition of claim 1 , wherein the β-amino acids are spatially aligned along a longitudinal axis of the analog in order to constrain the conformation of the analog in an active state.15. The composition of claim 1 , wherein the ratio of total β-amino acids to amino acids in the analog is from 1 to 3 β-amino acids for every 7 amino acids of the analog.16. (canceled)17. The composition of claim 1 , wherein the analog does not comprise a repetitive pattern of sequential β-amino acids from the amino-terminus to the carboxy-terminus selected from the following: ααααααβ claim 1 , αααααβα claim 1 , ααααβαα claim 1 , αααβααα claim 1 , ααβαααα claim 1 , αβααααα claim 1 , βαααααα claim 1 , αααααββ claim 1 , ααααββα claim 1 , αααββαα claim 1 , ααββααα claim 1 , αββαααα claim 1 , ββααααα claim 1 , βαααααβ claim 1 , βααααβα claim 1 , βαααβαα claim 1 , βααβααα claim 1 , βαβαααα claim 1 , αβααααβ claim 1 , ...

Prophylactic kit apparatus

A prophylactic kit apparatus configured to be used with only a single patient includes a plurality of sealed modules and a housing configured to contain those sealed modules such that only one of the plurality of sealed modules can be removed from the housing at a time. This kit may include a physically-discrete informational patient aid disposed within the housing and having information disposed thereon. By one approach these physically-discrete informational patient aids can have a bookmark form factor. So configured, a medical services provider can readily provide the physically-discrete informational patient aid to a patient to thereby facilitate the patient becoming informed regarding the corresponding prophylactic service with little or no burden on the service provider.

Peroxide formulations and methods and applicators for using the same

Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Device for the collection, refinement, and administration of gastrointestinal microflora

Devices and systems for isolating gastrointestinal microflora from stool collected from a donor are provided. Stool is collected from a donor in a container as the donor is defecating. A solvent is introduced into the container and the container sealed to place its contents in a sealed environment. Various agents can be added to achieve dissolving, colorizing, deodorizing, or for further therapies. The solvent and collected stool is homogenized into a mixture which is then filtered by a multi-stage filter system to create a solution containing microflora in the desired consistency. This solution can be dispensed via an enema tube or other delivery apparatus for infusion into a patient's gastrointestinal tract.

COMPOSITION DELIVERY DEVICE AND METHODS OF USE

A self-contained composition dosing and delivery system combination, such as described herein. The device also provides a dosing element internal the device chamber. In particular the device may be used to deliver liquid medicine. The device may also include child-proof means to reduce child poisoning due to Over-the-Counter (OTC) medication overdoses. 1. The method of dispensing a composition comprising:grasping a composition dispenser wherein the composition dispenser comprises; a composition housing wherein the composition housing comprises a storage reservoir and a delivery reservoir in fluid communication with one another via at least one fluid transfer opening, wherein the storage reservoir is configured to hold a composition prior to measuring a dose for a person and wherein the delivery reservoir is a chamber where the composition is dosed and delivered; a plunger wherein at least a portion of the plunger is positioned within the delivery reservoir and a lid member with a tip, wherein the lid member is movably coupled to the composition housing such that the tip is aligned with the delivery reservoir and is positionable to selectively close the at least one fluid transfer opening;positioning the lid member to open the at least one fluid transfer opening;drawing a portion of the plunger out of the delivery reservoir filling the delivery reservoir with a dose of the composition;rotating the lid member thereby closing the at least one fluid transfer opening and placing the drawn portion of the plunger in the delivery reservoir, thereby delivering the dose of the composition.2. The method of wherein the composition dispenser further comprises a cap wherein the cap is configured to removeably couple to the lid member.3. The composition dispenser of wherein the cap further comprises a push-activated child safety means.4. The composition dispenser of wherein the lid member further comprises a safety tab and the cap further comprises a tab receiver.5. The method of ...